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Abstract
McCanless, Jonathan Dempsey. PhD. The University of Memphis.
December/2011. Biomaterial-induced remodeling of subchondral and cancellous bone as
an early intervention to joint degeneration with focus on the spinal disc. Major Professor:
Warren O. Haggard, PhD.
Osteoarthritis-associated pain of the spinal disc, knee, and hip derives from
degeneration of cartilagenous tissues in these joints. Traditional therapies have focused
on these cartilage (and disc specific nucleus pulposus) changes as a means of treatment
through tissue grafting, regenerative synthetic implants, non-regenerative space filling
implants, arthroplasty, and arthrodesis. Although such approaches may seem apparent
upon initial consideration of joint degeneration, tissue pathology has shown changes in
the underlying bone and vascular bed precede the onset of cartilaginous changes. It is
hypothesized that these changes precedent joint degeneration and as such may provide a
route for early prevention. The current work proposes an injectable biomaterial-based
therapy within these subchondral and cancellous bone regions as a means of preventing
or reversing osteoarthritis. Two human concentrated platelet releasate-containing alginate
hydrogel/beta-tricalcium phosphate composites have been developed for this potential
biomaterial application. The undertaking of assessing these materials through bench-, in
vitro, and ex vivo work is described herein. These studies showed the capability of the
biomaterials to initiate a wound healing response in monocytes, angiogenic and
differentiation behavior in immature endothelial cells, and early osteochondral
differentiation in mesenchymal stem cells. These cellular activities are associated with
fracture healing and endochondral bone formation, demonstrating the potential of the
biomaterials to induce osseous and vascular tissue remodeling underlying osteoarthritic
joints as a novel therapy for a disease with rapidly growing healthcare costs.
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PREFACE
The main body of this dissertation is composed of the following three journal
articles: “Paralleling early hematoma function with human concentrated platelet
releasate-containing alginate/beta-tricalcium phosphate biomaterials for the early
prevention of osteoarthritis” submitted to Journal of Biomedical Materials Research Part
A, “In vitro inflammatory response and ex vivo delivery of an injectable platelet
releasate-containing alginate calcium phosphate composite for the early prevention of
joint degeneration” submitted to Acta Biomaterialia, and “In vitro differentiation and
biocompatibility of mesenchymal stem cells on a novel platelet-releasate containing
injectable composite” submitted to Journal of Biomedical Materials Research Part A.
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Chapter 1. Introduction
BACKGROUND
In 2010, the U.S. Department of Health and Human Services’ Health Cost and
Utilization Project (HCUP) reported osteoarthritic degenerative joint disease and
disorders of the spinal column (discs and vertebrae) accounted for an estimated 919,000
and 663,000 US primary diagnoses in discharged inpatients during 2008, respectively1.
These occurrences were ranked fourth and, presumably (based on reported data), tenth in
prevalence, excluding pregnancy and childbirth-related instances, and collectively
resulted in a financial burden of $23 billion as inflation-adjusted hospital costs for
primary diagnosis care1. Independently, the rate of the increased cost of treating each
osteoarthritis (not including the back) and spondylosis, intervertebral disc disorders, and
other back problems have more than doubled the rate of total hospital cost growth
between 1997 and 2008 from a percentage basis1. The Center for Disease Control and
Prevention concluded that care and management costs for arthritis and other rheumatic
conditions within the U.S. were an astounding $128 billion in 2003 when both direct and
indirect costs were considered, which corresponds to 1.2% of the gross domestic product
that year2. Degeneration is associated with an overwhelming majority of these cases (as
opposed to injury, neoplasm, infection, etc.), and as such, arthroplasty, in the case of
diarthrodial joints, and surgical-induced ankylosis for vertebral fusion are the most
common interventions employed for these unsalvageable joints3. These complex invasive
treatments explain the excessive immediate and persistent socioeconomic cost.
Joint prostheses have an obvious advantage over fusion due to at least a partially
preserved functionality4-7, but both of these clinically practiced treatments are plagued
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with exorbitant costs, native tissue morbidity, and extensive rehab/recovery, and the
possibility of unforeseen complications or long in-life periods can result in traumatic
revision surgery8-10. This presents a need for improved, more economical treatment
modalities, especially in regard to the disc11,12. Surgeons, scientists, and engineers have
made many attempts to restore functional, biomechanically stable cartilage within the
articulating joints of the knee and hip through grafting procedures with little to no
repeatable success13,14. Use of resorbable, regenerative biomaterials within knees and hips
is an attractive possibility but has traditionally performed less effectively than grafting.
Novel disc therapies which avert fusion involve removal of diseased tissue and may also
include application of a permanent implant material within the nucleus region15. Removal
of tissue, implant materials, and fusion cause biomechanical instability within the spine
and typically produce degeneration in adjacent tissue (faucet, discs, ligaments, etc.)15.
These inconsistent and failed attempts suggest the underlying causes of cartilage
degeneration are not being circumvented by these current clinical practices and
researched treatments and illicit consideration of regenerative-type therapies which do
not focus directly on the nucleus and endplate of the disc or the articular cartilage of the
hip and knee.
Taking a step back and studying the etiology of osteoarthritis, versus its ultimate
finale of cartilage destruction, presents reasoning for pursuit of an early treatment via a
bone restoration approach. Accompanying joint degeneration, and manifesting prior to
complete cartilage failure, the underlying subchondral and cancellous bone undergoes
progressive changes16. Most notably is advancing calcified cartilage (tidemark) early in
the disease, and osteophyte formation around invading vessels in the more advanced
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state16. Accompanying abnormal subchondral plate thickness, adjacent trabecular bone
mineral density increases with alterations in architecture, resulting in brittleness16. Within
the knee and hip, bone may become necrotic in severe cases, eventually collapsing under
physiological loading, resulting in destruction of the articular surfaces17,18. In the spine,
and paralleling knee and hip subchondral plates, the vertebral cortex thickens adjacent to
the disc, causing occlusion of vascular diffusion pathways which metabolically link the
disc to the surrounding vertebral bodies19,20. These occlusions lead to a buildup of waste
products and a lack of nutrients within these joints, most notable within the disc21-23.
Urban et al. and her co-worker Maroudas et al. experimentation and theoretical work
demonstrated the need of biomechanical “pumping” assistance for diffusion within the
knee, in the late 1960’s and 70’s22,24,25. Given this requirement, it is reasonable to believe
that the loss of the underlying nutrient pathway in all of these joints leads to the cellular
apoptosis and tissue turnover associated with early stages of degenerative disease. The
anatomy of the discs exemplifies the need for diffusion in its excessive thickness and
annulus containment where evidence of nucleus pulposus alterations precede disc
degeneration15,17,19,26. As disc disease progresses, osteophytes and vessels invade,
bringing nerve ending and the associated pains of osteoarthritic compression, as well as
pains related to vertebral collapse on nerve ganglia. Alternatively, pains within
diarthrodial joints are typically the result of bone-on-bone contact from diarthrodial
articular cartilage legions17,19,27,28. Regardless, both conditions are the result of Type II
cartilage failure in vertebral endplates and articular surfaces.
Traditionally, the onsets of such tissue abnormalities have been used as a means
of diagnosing the onset of a diseased state via various imaging techniques27-30. Although
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disease pathologists and bone biologists have suspected that these underlying bone
abnormities plays a major role in cartilage degeneration16,19, most specifically within the
changes of the vascular bed the vertebral cortex20, little to no attention has been given to
these observations in regard to a potential treatment, and exploration of such may reveal a
novel subchondral bone-based remodeling therapy for osteoarthritis within knees, hips,
and, most notably, spinal discs.
The current work proposes a strategy to remodel unhealthy bone tissue to that of a
healthy state as a means of circumventing the progression of degeneration within afflicted
joints. Resorption of bone associated tissue is mediated by osteoclasts and macrophages
which are differentiated from monocytes31. Recruitment of monocytes cells may be
induced through chemokine such as those released from activated platelets as is found in
a blood clot or hematoma32,33. Additionally, as this bone is being resorbed new healthy
bone and vasculature need be formed, restoring the diffusion pathway to the adjacent
joint. Local delivery of a composite biomaterial which delivers these bioactive agents and
is incorporated with an osteoconductive phase would allow for such a therapy as has been
described above.
HYPOTHESIS
Use of a minimally invasive implant system to induce the remodeling of
unhealthy subchondral and cancellous bone tissue underlying osteoarthritic joints, early
in the disease state, will decrease if not reverse further development of joint degeneration.
A biomaterial implant for this remodeling approach should be autologously bioactive,
resorbable, and demonstrate functionality similar to that of a hematoma as found with
fracture healing.
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Chapter 2. Paralleling early hematoma function with human concentrated platelet
releasate-containing alginate/beta-tricalcium phosphate biomaterials for the early
prevention of osteoarthritis
AUTHORS
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ABSTRACT
There is a significant gap in our understanding of underlying subchondral and
cancellous bone changes that may regulate osteoarthritic disease progression. In this
study we complement our prior osteochondrogenesis1 work with growth factor elution
and monocyte and endothelial cell activation in regards to two biomaterial formulations.
The design of these biomaterials was inspired by the roles of a fracture hematoma, more
specifically, the potential of significant cross-talk among cells and cellular factors that
affect bone remodeling. Biomaterials, referred to herein as F1+ and F2+, are human
concentrated platelet releasate-containing alginate/beta-tricalcium phosphate composites.
F1+ composition has a higher calcium phosphate volume percentage and lower alginate
polymer weight percent hydrogel in comparison to F2+. The majority of releasate-derived
platelet-derived growth factor eluted over twenty-four hours for F1+ and forty-eight
hours for F2+, suggesting sustained release with an increase in alginate weight
percentage. Simple monocyte and endothelial cell migration studies demonstrated 650%
5

and 900% increases with F1+ eluate over medium alone, respectively. The ability to
induce endothelial cell invasion over supplemented medium positive control was also
shown for F2+ eluate (p = 0.03) with F1+ eluate being similar to the control. Monocyte
transendothelial migration was increased over 300% and 400% for F1+ and F2+ eluates
compared to medium alone, respectively. Additionally, F1+ and F2+ eluates induced
spontaneous endothelial tube formations in a similar fashion to serum-supplemented
medium, demonstrating a well-formed network of capillary-like cell structures. This work
demonstrated our biomaterial formulations ability to induce characteristics in vitro that
parallel the in vivo behavior of a fracture hematoma and potential to induce bone
remodeling for the early treatment of osteoarthritic joints.
INTRODUCTION
It has long been recognized that age-related changes in the subchondral and
cancellous bone adjacent to cartilaginous joints precede the onset of osteoarthritic joint
failure; these changes are both vascular and calcified tissue in nature2-4. Recognition of
such is typical of clinical diagnosis or seen as a disease etiology of degenerative joint
disease, but little research effort has addressed these changes as a means of preventing
age-related degenerative joint failure progression. Treatment of such disease has
commonly required patient perseverance of pain for continued joint function and late
stage surgical intervention, be it arthroplasty, for hips, knees, and, as of recent, spines, or
arthrodesis, as is more frequently enlisted for debilitating intervertebral discs5-8. These
management treatments/therapies are an ongoing burden from a patient psychological,
patient financial, and healthcare cost perspective. We believe that an early, cost efficient
preventive treatment addressing osseous and vascular tissue irregularities which would
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require limited patient demands at the onset of early stage disease-related joint failure
would serve as a major step towards improving clinical outcomes for osteoarthritis.
The following work presents our continued in vitro exploration of a biomaterial
intervention for the onset/progression of osteoarthritic joint failure via bone remodeling.
Our proposed implant system is modeled after natural and implant-assisted fracture
healing and presents a bioresorbable osteoconductive scaffold after an initial, short-term
delivery of growth factors. This study and our prior work suggest that osteochondral
differentiation9, immune responses associated with tissue/implant resorption, and osteoand angiogenic growth factors are deliverable from the composite biomaterials. The
included bioactive agents for these composites have been obtained through blood
processing protocols which are customary within the clinical setting10, allowing for a
low-cost autologous source. In prior work, currently in review, we showed the ability of
these materials to activate monocytes, a process required for immune cell mediated
resorption and phagocytosis of unhealthy tissue, ability to stimulate mesenchymal stem
cell (MSC) osteochondral differentiation in vitro, and ability to be injected and stably
retained within rat caudal vertebrae ex vivo1,11. With this study, we intensely investigate
in vitro biomaterial-induced monocyte and endothelial cell motility and evaluate plateletderived growth factor elution. Our findings from the current study are indicative of
immune and angiogenic responses that are required for bone remodeling.
MATERIALS AND METHODS
Biomaterial Formulations and Preparation
Table 1 details the compositions of experimental formulations F1+ and F2+ which
were created through syringe mixing. A syringe containing sodium alginate (Sigma; St.
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Louis, MO) solution at twice the final concentration was coupled to a second containing
125-150 µm beta-tricalcium phosphate (β-TCP) granules (Plasma Biotal, Ltd.;
Derbyshire, United Kingdom), calcium sulfate dihydrate (USG Corp.; Chicago, IL),
human concentrated platelet releasate (hCPR), and, for F2+, sodium citrate (Fisher;
Waltham, MA). Components were mixed by twenty passes between the coupled syringes,
which also initiated an ionic polymerization setting reaction. This mixture can be easily
delivered through injection via a 16-gauge hypodermic needle prior to curing.
Additionally, material controls with deionized water replacing hCPR were created and
designated as F1- and F2-.

Table 1. Experimental Formulations
*Volume percent based on B-TCP density of 3.14g/cm^3
**wt% based on gel portion only
***L/P is equal to gel volume in milliliters divided by calcium sulfate mass in grams
****Molarity is based on gel volume only.
Calcium
ΒSodium
Formulation
Liquid
Sulfate
TCP*
Alginate**
(L/P***)
50% (v/v) water;
20
2 wt%
300
F1+
50% (v/v) hCPR
vol%

F2+

50% (v/v) water;
50% (v/v) hCPR;
5 mM trisodium-citrate****

10
vol%

8 wt%

100

hCPR was prepared under an Institutional Review Board-approved protocol at the
University of Memphis (approval IRB #/date: H11-16/September 9, 2010) through
methodology adapted from White and Jennings12. Processing was conducted at room
temperature unless noted differently. ~120 ml of blood was acquired by venipuncture into
30 cc syringes and transferred to 50 ml conical polypropylene tubes containing citrate
buffer. Plasma and buffy coat supernatants were collected after centrifugation (600 g).
8

Platelets were then concentrated in plasma through further centrifugation (2,000 g),
removal of the upper cell-free plasma (80% volume reduction), and resuspension into the
remaining plasma. Platelet-rich plasma (PRP) was pooled (n = 5), and clotted with 10%
(wt/v) calcium chloride (50 µl/ml of PRP). Clotting occurred for one hour at 37° C. hCPR
was expelled from the clot, sterile filtered (0.20 µm), and stored at -80° C.
Specimens for this work were created using sterile materials. Alginate solutions
were autoclaved. Calcium salts were gamma irradiated. Sodium citrate, hCPR, and
deionized water (for F1- and F2- formulas) were sterile filtered; sterile sodium citrate
solutions were lyophilized in syringes equipped with 0.20 µm syringe filters to obtain a
sterile solid. Test specimens were created with ~3 ml mixes which were allowed to cure
within 3 cc syringes; after curing (~10 minutes), syringe injection ports were cut off and
cylinders of the material were expelled and cut to size.
Platelet-Derived Growth Factor (-BB and -AB) (PDGF) Elution
Growth factor release was assessed through elution studies with PDGF sandwich
enzyme-linked immunosorbent assays (ELISAs) (PeproTech; Rocky Hill, NJ). Elution
was conducted from 1.5 ml specimens into 0.1 wt% albumin in phosphate buffered saline
(PBS) eluent at 37°C (n = 4). 1.5 ml samples were pulled from an initial 40 ml at 5 hours,
1, 2, 3, and 5 days. Additionally to monitor PDGF depletion, 400 µl of hCPR was added
to 40 ml eluent and sampled at time zero, 5 hours, 1, 2, 3, and 5 days (n = 3). PDGF
concentrations were taken as the average of duplicate ELISA measurements. Material,
specimen number, and time were taken as independent experimental variables.
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In Vitro Monocyte Motility
Simple chemotaxis was assessed with the RAW 264.7 clone TIB-71TM (ATCC;
Manassas, VA) monocyte/macrophage cell line (monocytes) using 24-well Transwell®
plates with 3 µm pore polycarbonate inserts (Corning; Lowell, MA). Lower wells were
loaded with Dulbecco’s modified Eagle’s medium (DMEM), 10-8 M n-formyl-methionylleucyl-phenylalanine (fMLP) in DMEM, or 48 hour eluates of F1+, F2+, F1-, and F2-.
Eluates were produced with 1.5 ml material specimens in 5 ml of DMEM. Cell TrackerTM
Orange (Lonza; Basel, Switzerland) labeled monocytes (3 µM) were loaded into upper
wells in DMEM (105 cells/insert), and migration was allowed to occur for 4 hours (n =
2). Those cells which did not migrate were removed using a PBS dampened cotton swab,
and those which had migrated were collected in the lower well through centrifugation
(400 g, 15 minutes) of the plate with inserts installed. Cells in lower wells were then
suspended via micropipette mixing and counted indirectly using fluorescence
spectroscopy and a standard curve of monocytes which had been seeded at the start of the
experiment. Values were taken as the average of duplicates.
Transendothelial migration was assessed using a very similar methods as
described above with 8 µm inserts (n = 2); all differences are noted in the following.
Lower surfaces of inserts had been coated with bovine collagen type I (50 µg/ml for 1
hour), and upper surface was coated with 50 µl of 50 µg/ml growth factor-reduced
MatrigelTM (BD Biosciences; Franklin Lakes, NJ).
A confluent endothelial monolayer was established on upper insert surfaces using third
passage primary human umbilical vein endothelial cells (HUVECs) (ATCC). 104
HUVECs were seeded on the upper insert surface and allowed to expand for five days in
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bovine brain extract endothelial cell growth kit (BBE) (ATCC)-supplemented M200
(Invitrogen; Carlsbad, CA) with daily medium changes.
In Vitro Endothelial Cell Motility
Simple chemotaxis of HUVECs was assessed on upper and lower surface
collagen-coated 8 µm inserts. Lower wells contained M200, BBE-supplemented M200,
or DMEM material eluates. HUVECs were starved overnight in 0.5 vol% fetal bovine
serum (FBS)-supplemented M200 and plated at 5x104 cells/insert in M200. Migration
was allowed for 4 hours. After which, cells on the upper insert surfaces were removed
with a PBS-dampened cotton swab, and those which had migrated to the lower surface
were cold shocked with 0°C PBS and fixed with -20°C methanol on ice. Fixed cells were
labeled with 10 µM ethidium homodimer-1 (EthD-1) (Invitrogen) in PBS and imaged
using fluorescence microscopy. Four frames of view (100x) per insert were captured and
cells counted using FIJI/ImageJ software (NIH; Bethesda, NJ). The experiment was
repeated to confirm trends in the results.
Enzymatic HUVEC invasion was performed in 8 µm inserts through 50 µl of
MatrigelTM diluted 1:3 with M200. Cells were starved overnight, plated at 1.5x105
cells/insert in M200, and allowed 30 hours to migrate to the lower surface. Experimental
groups, fixation processing, staining, and image acquisition was identical to that
described above for the simple chemotaxis assay. Image analysis was again performed
with FIJI/ImageJ software using 100x fluorescent micrographs, but total cell area (µm2)
was used as opposed to raw cell counts. The experiment was repeated to confirm trends
in the results.
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Spontaneous Endothelial Tube Formation
The ability of materials to induce HUVEC tube formation on MatrigelTM blends
was studied. M200, BBE-supplemented M200, or using DMEM material eluates were
mixed with MatrigelTM at 2:1 volume ratios. 65 µl of blends were put in 96-well plates (n
= 3). 5x104 second passage HUVECs were seeded on gel surfaces. Tube formation was
assessed using digital 40x micrographs of the cultures 12 hours after seeding. FIJI/ImageJ
software was used to analysis tube formations; total tube length (µm), number of tubes,
and number of junctions were determined.
Statistical Analysis
Statistical analysis of all data was performed using SAS® software (Cary, NC).
ANOVA (α = 0.05) was used for main factor(s) effect tests in ELISA and motility data.
Tube formation data was subjected to MANOVA with Wilks’ Λ test statistic (α = 0.05) to
detect main factor effects and canonical correlation analysis to assess the existence of
relationships among the dependent variables. Tukey HSD post-hoc analyses were
conducted in the event that main factor effects were detected.
RESULTS
PDGF Elution
PDGF was observed to accumulate within eluents as it diffused from F1+ and
F2+; depletion of PDGF in the experimental setup was monitored separately, through
spiking eluents with hCPR. Both accumulation and depletion were monitored over a five
day period (Figures 1 and 2, respectively). Early release values (5, 24 and 48 hours;
Figure 1) suggest a more sustained release from F2+, the formula containing a higher
weight percentage of alginate, as compared to F1+. Although due a lack of data points,

12

the interaction effect of time and material could not be considered in the formal analysis,
leaving release rate differences speculative. Without temporal consideration, no
significant difference was detected between the materials, but alternatively, values were
found to increase with time (p = 0.0033). Additionally and with some insinuation about
F2+ having a slower release rate, variance among specimens was found significant (p =
0.0027). Independent post-hoc grouping of specimen and time factors showed two F2+
specimens released significantly less PDGF than one F1+ specimen and 5 hour PDGF
accumulation was significantly lower than that at 120 hours, respectively. Finally, the
depletion experiment revealed a loss of PDGF with time (p < 0.0001) which was
indistinguishable between specimens. The average concentration of the spiked eluents
had depleted 65% by 120 hours.

Figure 1. Platelet-Derived Growth Factor (-BB and -AB) (PDGF) Release From F1+
And F2+
PDGF release was tracked for each specimen individually (n = 4 per material) at 5, 24,
48, 72, and 120 hours. Concentration values were determined through ELISA. Based on 5
and 24 hour data, F1+ appears to release growth factors at an accelerated rate compared
to F2+; this observation is in-line with F1+ having a lower weight percentage of alginate
compared to F2+, corresponding to a lower diffusion coefficient. Significant differences
were found when individual specimen profiles were considered (p = 0.0027) and support
F1+’s accelerated release rate with two F2+ specimens eluting significantly less PDGF
than one F1+ specimen. Average values are indicated by markers with plus and minus
one standard deviation error bars shown for F1+ and F2+, respectively.
13

Figure 2. Loss Of ELISA Detectable Platelet-Derived Growth Factor (-BB and -AB)
Within Experimental Setup
Data show 0, 5, 24, 48, 72, and 120 hour concentrations (n = 3). The system
demonstrated a consistent depletion of PDGF out to 72 hours; this loss with time was
found significant (p < 0.0001). At 120 hours an average 65% of the initial PDGF was
undetectable. This loss may be the result of protein degradation resulting from unfolding
or enzymatic chemical degradation and/or protein adsorption to vessel walls. Data are
shown as average values with error bars indicated plus/minus one standard deviation.

In Vitro Monocyte Motility
Monocytes demonstrated inflammatory-related chemoattractant properties of
eluates from both experimental and material control specimens (Figure 3). 74% and 83%
of seeded monocytes had migrated to the lower wells containing F1+ and F2+ eluates in
the simple migration assay (Figure 3a), respectively. Eluates corresponding to material
controls F1- and F2- also showed the ability to attract monocytes, although to the lesser
extent, at 23% and 24% cell migration, respectively; these material control values were
still a significant increase over the DMEM negative control (p ≤ 0.03). Fewer monocytes
had migrated in the more demanding transendothelial migration assay where 54% and
67% of seeded cells had relocated to the lower wells for F1+ and F2+ eluates (Figure 3b),
respectively. Nevertheless, F1- and F2- eluates were able to induce significantly more
monocytes to transverse the HUVEC monolayer than the DMEM negative control (p ≤
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0.004). Unfortunately, the fMLP positive control did not demonstrate chemoattractant
properties in either assay at the low concentration tested (10-8 M) and was
undistinguishable from the DMEM negative control in post-hoc test results.

Figure 3. RAW 264.7 Clone TIB-71TM Mouse Monocyte Migration Assays Results
F1+, F2+, F1-, and F2- groups indicate the use of material eluates. n-formyl-methionylleucyl-phenylalanine (fMLP) was used as a positive chemotactic control at 10-8 M
unsuccessfully, and Dulbecco’s modified Eagle’s medium (DMEM) was used as a
negative control. 105 monocytes were placed in the upper inserts of Transwells® and
allowed to migrate towards experimental and control solutions in the lower well. Both
assays demonstrate the inherent nature of the alginate/beta-tricalcium phosphate raw
materials to induce some monocyte activation (F1- and F2-) with enhanced ability being
shown for the experimental, human concentrated platelet releasate-containing materials
(F1+ and F2+) (Figure 3A and 3B). Data show average values with error bars indicated
plus/minus one standard deviation. Figure 3A (left) shows simple chemotaxis results
through 3 µm polycarbonate Transwell® inserts. Figure 3B (right) shows tranendothelial
monocyte migration through 8 µm polycarbonate Transwell® inserts.

In Vitro Endothelial Cell Motility
Results from the HUVEC motility assays demonstrated angiogenic-related
chemoattractant qualities with these primary cells for both experimental and control
material eluates (Figure 4). Experimental F1+ material eluate clearly induced a
significant increase in HUVEC migration over all other groups in the simple migration
assay (p ≤ 0.0001). Whereas, experimental F2+ material eluate and positive control BBEsupplemented M200 values only approached significant increases over the negative
15

control M200 in this assay (p = 0.0616 and 0.0672, respectively). Although to a lesser
degree than its hCPR-containing experimental counterpart eluate, F1- eluate was able to
induced simple HUVEC migration over the M200 negative control (p = 0.0455).
Haptotactic activities of HUVECs in the invasion assay were much more evident of
effects and differences. The ability to induce a strong enzymatic-driven invasion from
HUVECs was apparent with the 30-fold increase over M200 alone due to BBEsupplementation in negative and positive controls (p < 0.0001); significant increases
above the negative control were seen for all other groups (p ≤ 0.0003). F1+ and F2+
eluates individually induced greater endothelial invasion than their control material
counterparts F1- and F2- (p = 0.0024 and 0.0033, respectively). Additionally, F2+ eluate
suggested the greatest chemoattractant ability for these cells, being the only group to
significantly exceed the positive control with an average 52% increase in lower insert
surface cell coverage area (p = 0.0038) which also corresponded to an average 22%
increase over F1+ eluate values.
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Figure 4. Human Umbilical Vein Endothelial Cells (HUVECs) Migration Assays Results
F1+, F2+, F1-, and F2- groups indicate the use of material eluates. M200 medium and
bovine brain extract kit-supplemented M200 medium served as negative and positive
controls, respectively. Both assays demonstrate the inherent nature of the alginate/betatricalcium phosphate raw materials to induce some HUVEC activation (F1- and F2-) with
enhanced ability being shown for the experimental, human concentrated platelet
releasate-containing materials being evident for F2+ only in the invasion assay (Figure
4B) and F1+ demonstrating this enhancement in both assays (Figure 4A and 4B). Data
show average values with error bars indicated plus/minus one standard deviation. Figure
4A (left) shows the simple migration of HUVECs across 8 µm TranswellTM inserts.
Figure 4B (right) shows enzymatic-driven HUVEC invasion through basement
membrane gels on 8 µm polycarbonate Transwell® inserts.

Spontaneous Endothelial Tube Formation
In vitro angiogenesis was further assessed through the ability and extent of
spontaneous tube formation by HUVECs (Figure 5). Qualitatively, micrographs of
experimental material eluates from F1+ and F2+ produced more uniform cell
organization networks. Organizations within the experimental groups demonstrated
wider, continuous branches, and less cell compaction at junction points, while other
groups demonstrated smaller branches with greater width variability and multiple
branches which terminated on the substrate as opposed to continuity between two
junction points. MANOVA of image analysis results for total tube length, tube count, and
junction count demonstrated a Wilks’ Λ = 0.081 (p = 0.0098) with the large majority of
accountable variance within the model stemming from the effect of MatrigelTM blend
17

type on total tube length; blend type did not demonstrate significance in tube and junction
count variance. However, and as expected, from the nature of such branching network
systems, tube and junction count were predictive of one another, producing high
canonical correlation (0.9726). Reflecting back on length measures, F1+ eluate, and to a
lesser degree, F2+ eluate demonstrated superiority in total length measures over their
non-hCPR containing counterparts with 255% and 220% increases (p = 0.0024 and
0.0192, respectively).
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Figure 5. Human Umbilical Vein Endothelial Cells (HUVECs) Spontaneous Tube
Formation Assay On Basement Membrane Gels
F1+, F2+, F1-, and F2- groups indicate the use of material eluates. M200 medium and
bovine brain extract kit-supplemented M200 medium served as negative and positive
controls, respectively. Images were captured after 12 hours. ImageJ software was used to
determine total branch length, branch count, and junction count, shown in Figure 5A, 5B,
and 5C as average values with bars showing plus/minus one standard deviation.
Multivariate analysis determined the eluate/media test factor to have a significant effect
on tube length (p = 0.0098). Figure 5A shows the results from the total branch length
analysis and demonstrates increased total branch length from F1+ and F2+ eluates in
comparison to their counterparts which did not contain human concentrated platelet
releasate (p = 0.0024 and 0.0192, respectively). Figures 5B and 5C show the results from
total branch count and total junction count measures, respectively; neither variable was
found to be effected as a result of eluate/media type. Figure 5D shows representative F1+
tube formations, which were similar to F2+. Figure 5E shows representative F1- tube
formations, similar to F2- and M200 medium. Figure 5F shows bovine brain extract kit
(BBE)-supplemented M200 group with the ImageJ created overlay of the branch skeleton
used to generate the raw branch and junction data. F1+ and F2+ groups consistently
demonstrated a well formed network of branches which terminated at junction points; this
observation was similar to that see for M200 + BBE. Branches for the experimental F1+
and F2+ groups typically were thicker in diameter/width, qualitatively. F1-, F2-, and
M200 groups, which did not contain growth factors, produced poorly formed networks
and generally retracted into cell masses, seen in Figure 5E. Upon close inspection of
Figure 5E, it is apparent that multiple, small branches that often terminated on the gel
itself were seen protruding from individual junctions from the cell masses and explain
why the number of branches and junctions were not found to be significantly affected by
the various groups.

19

DISCUSSION
In the current work, we have demonstrated in vitro the capability of our
biomaterial composites to induce motility in both a monocyte cell line and primary
immature endothelial cells, conjugated motility of monocytes through a confluent
monolayer of endothelial cells, modeled haptotactic-induced endothelial cell passage
through basement membrane-derived gel, and observed spontaneous induction of
endothelial cell tube formation all of which reflect on immune and angiogenic responses.
Collectively the current and our prior findings of monocyte activation and
osteochondrogenesis have confirmed the hCPR-containing alginate/β-TCP composites’
ability to induce an in vitro response similar to that which occurs early within a fracture
site and, more specifically, hematoma-initiated inflammation and angiogenic-type
behaviors. These responses are hypothesized as a potential biomaterial-instigated
remodeling of bone tissue. Healthy reformation of bone and vascularization adjacent to
joints exhibiting early stages of degeneration is proposed as a means of reversing or, at a
minimum, inhibiting the advancement of the age-related disease (osteoarthritis) through
addressing these detrimental bone changes.
Our injectable, in situ curing biomaterial has been designed as a biologically
active implant system through use of hCPR as an autologous source of growth factors and
cytokines. The delivery of such bioactive agents was modeled through PDGF elution in
the current work. The alginate hydrogel served as a carrier and was the bulk of the
implant, allowing for diffusion-controlled release of active proteins from the contained
osteoconductive environment (β-TCP granules). The material is designed such that the
osteoconductive granules would be exposed in an outside-in manner as the alginate
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carrier is degraded through surface dissolution, chemical degradation, mechanical
degradation, and apparent phagocytosis by macrophages and other phagocytes13.
Physiological tolerance and release of bioactive agents and cells from alginatebased systems have been well documented14-16, and our findings share commonality with
the known induction of the overlapping, early stages of fracture healing17,18.
Chemoattraction of monocytes and HUVECs corresponds to the early “inflammatory
stage” and vascular ingrowth into stroma in the “repair stage”, respectively17. These
cellular responses are necessary for fracture repair and occur within the hours to days
post-fracture time frame17,18. This short time frame is in agreement with the PDGF
release profile and chemoattract characteristics of the 48 hour eluates demonstrated in
this study, supporting our objective of mimicking a fracture hematoma-like response.
Release profiles of other growth factors from the materials are expected to be similar to
that of PDGF, due to the hydrophilic nature of the polymer which discourages protein
adsorption19,20. hCPR was chosen for inclusion due its content of multiple growth factors
and cytokines associated with proliferation, pro- and anti-inflammatory responses, and
chemoattracts; additionally it is relatively easy to acquire in an autologous manner within
a clinical setting using commonly available equipment21-23. The multiple cell-based
assays performed confirm that functionality of the various growth factors is maintained
through the implant mixing and curing process. Curing is accomplished through ionic
cross-linking of the alginate polymer strands24. This cross-linking method of gelling is
much gentler and biocompatible from a chemical stand point in comparison to the
reaction methods of chemical cross-linkers associated with other hydrogel systems19.
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Our findings suggest that induced chemotaxis in RAW264.7 TIB-71TM and
HUVEC cells is a result of both hCPR-derived growth factors and responses to the
implant raw materials. Alginate has been shown to induce mild inflammatory responses
in vivo as a result of purity, M:G monomer ratio, and molecular weight25,26. The current
study demonstrated this suggestion with use of the material control groups F1- and F2eluates which induced simple chemotaxis and transendothelial monocyte migration. The
inclusion of hCPR was found to enhance this inherent inflammatory response by
increasing the number of migrated cells within a given time. These responses agree with
our prior work in which nitric oxide accumulation in monocyte cultures exposed to F2+
and F2- were above basal levels with F2+ having the greatest accumulation11. Yang and
Jones have shown alginate-induced activation of RAW264.7 cells via the NF-κB pathway
activation, similar to that of pathogen-induced activation27. Mouline, et al. demonstrated,
independently, RAW264.7 and human blood-derived monocytes grown within a plasma
clot surrounding 80 – 200 µm biphasic calcium phosphate (β-TCP and hydroxyapatite)
particles to produce gene expressions consistent with osteoclastogenesis28. Additionally,
they detected the expression of mRNA for signaling molecules which are associated with
angiogenesis and chemotaxis28. It was concluded that such responses are accountable for
the known osteogenic capabilities of their material28. Their use of the RAW267.7
monocyte line and material design of calcium phosphate in a plasma clot allow for near
direct comparison with our findings of angiogenic, chemotactic, and haptotactic cellular
activities which corresponds well with their gene expression profiles. Also of relevance,
the osteoconductive β-TCP granules served as a source of calcium ions through surface
dissolution. Although calcium is not a chemotactic agent per se, flux of calcium across
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endothelial cell ion channels is a requirement for multiple cell functions, including
angiogenesis29. Calcium is essential for endothelial cell attachment, maturation,
proliferation, spreading, and response to chemotactic agents30,31. Alternatively, some
functions in HUVEC cells required calcium and growth factor presence as in the tube
formation assay where calcium works with other factors to allow this unique cell
function. Experimental material eluates F1+ and F2+ and serum-supplemented medium
were the only groups to form tube-like structures and the only groups with both calcium
and growth factors present. Our biomaterial composites have been designed such that the
alginate, β-TCP, and hCPR function concurrently and compliments one another in our
attempt to at reproducing a fracture hematoma-like response for bone remodeling.
In line with our hypothesis, early release of immunogenic and angiogenic factors
should induce an early tissue remodeling phase paralleling that of a fracture. Attraction of
monocytes and endothelial cell budding is expected to result in tissue and implant
resorption and installment of neovasculature, respectively, and collaboratively, in the
transition into the later stages of osteoconductive material-assisted osteoid deposition.
The capability of experimental materials F1+ and F2+ to elute functional proteins in-line
with this objective has been demonstrated through the chemotactic and haptotactic
abilities of eluates from these materials in vitro.
Incorporation of hCPR within F1+ and F2+ alginate-containing biomaterial
composites allows for controlled release of autologous bioagents. The releasate
supplemented the inherent material-induced initiation of monocyte and endothelial cell
recruitment that is associated with the early occurrences of bone tissue remodeling and
induced a well-organized endothelial tube networks. This induction may lead to healthy
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osseous tissue regeneration and be associated with the delay or reversal of joint
degeneration through rejuvenation of this underlying, unhealthy tissue.
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Chapter 3. In vitro inflammatory response and ex vivo delivery of an injectable
platelet releasate-containing alginate calcium phosphate composite for the early
prevention of joint degeneration
1. AUTHORS
Jonathan D. McCanless MS; Lisa K. Jennings PhD; Joel D. Bumgardner PhD; Judith A.
Cole PhD; Warren O. Haggard PhD
2. ABSTRACT
Alterations in the underlying subchondral and cancellous bone adjacent to
osteoarthric spine, knee, and hip joints precede the onset of painful cartilaginous tissue
failure. A biomaterial intervention which induces an inflammatory response early after
implantation, similar to a hematoma, and later introduces an osteoconductive scaffold is
anticipated to parallel fracture healing and induce remodeling of this osseous tissue to a
healthier state. The in vitro inflammatory responses of two human concentrated platelet
releasate-containing alginate/beta-tricalcium phosphate biomaterial strategies are
presented. The examination of the capabilities of these biocomposites to induce an
inflammatory response in TIB-71TM RAW264.7 mouse monocyte cell line cultures
through temporal measures of inducible-nitric oxide synthase gene transcription patterns
and media nitrite levels are reported. An inherent measurable inflammatory response
from these materials was found in addition to incorporated platelet releasate.
Composition differences in polymer weight percentage (2 vs. 8%) and/or granule volume
percentage (20 vs 10%) resulted in bioagent release profiles which suppressed responses
from non-existent or augmented upregulation of upstream gene expression 2.5-fold and
downstream nitrite levels 10-fold, the later being similar to endotoxin-induced response.
These in vitro results suggested a complex interaction between the inflammatory
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mediators of the platelet releasate and the biomaterial components. Additionally, the
ability to deliver this implant system via injection for in situ curing was demonstrated in
rat tail vertebrae with µCT.
3. INTRODUCTION
Clinically, degeneration of the cartilaginous structures of the intervertebral discs
and the articular surfaces of the knees and hips are managed by drugs and exercise and
allowed to progress to a near debilitating state prior to invasive arthroplasty surgery [1-4].
Changes in the underlying bone and vasculature typically precede the onset of
degenerative joint disease [4], suggesting an etiological role of the adjacent osseous
tissue. Development of reduced vasculature, subchondral plate thickening, and altered
trabecular architecture has been associated with osteoarthritis progression within these
joints [3-6]. Disease-associated bone and vessels result in an altered physiology and
shortcomings in the diffusion of nutrients and waste products to and from the resident cell
populations of affected cartilaginous tissues [4, 5, 7]. Hence an early intervention to
osseous tissue alterations may provide a preventative treatment strategy for joint
degeneration.
We speculate that the risks, trauma, and cost of an early, minimally invasive
treatment to joint degeneration would overcome the potential demands of arthroplasty
and present continued in vitro and ex vivo assessment of our biomaterials for such
therapy. The therapeutic biomaterial design was confined around the concepts of bone
graft substitutes, endochondral ossification, and the role of hematomas in fracture
healing, all of which are associated with the formation of healthy, vascularized bone and
some of which encompass resorption of ailed bone and materials [8-11]. Our objective is
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to remodel osseous tissue associated with joint degeneration to a healthier state prior to
an advanced stage of osteoarthritis through injection delivery and in situ curing of these
biomaterials within the adjacent subchondral and cancellous bone region.
Previous in vitro studies assessed our human platelet releasate-containing alginate
hydrogel/beta-tricalcium phosphate (TCP) composites as candidates for the above
proposed biomaterial therapy [12]. In those studies the composites initiated murine
mesenchymal stem cell differentiation along the early stages of osteochondrogenesis via
multiple gene expression patterns [12]. While these data are promising,
neovascularization and activated proinflammatory cell-mediated resorption of irregular
mineralized tissue and the implant are also essential processes for osseous tissue
rejuvenation and the remodeling of subchondral bone. Increased vascular density is
necessary for metabolic support and delivery of mesenchymal and immune cells involved
in the remodeling process [10, 13]. Our study aims to expand previous work with these
biomaterials through examinations of the inflammatory response of a
monocyte/macrophage immune cell line upon exposure to the alginate/TCP composites in
vitro and ex vivo evaluation of a composite injected within rat tail vertebral bodies.
4. MATERIALS AND METHODS
4.1 Biomaterial Platform
Two injectable alginate hydrogel/TCP granule composites containing bioactive
concentrated human platelet releasate (hCPR), designated as F1+ and F2+, are described
in Table 1. The formulations are designed such that the alginate weight percentage and
the TCP volume percentage are inversely related. An additional, non-biologic
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formulation designated F2- was created identical to F2+ with the exception sterile
deionized water replacing hCPR.

Table 1. Experimental Formulations
*Volume percent based on B-TCP density of 3.14g/cm^3
**wt% based on gel portion only
***L/P is equal to gel volume in milliliters divided by calcium sulfate mass in grams
****Molarity is based on gel volume only
Calcium
ΒSodium
Formulation
Liquid
Sulfate
TCP* Alginate**
(L/P***)
50% (v/v) water; 50% (v/v)
20
2 wt%
300
F1+
hCPR
vol%
F2+

50% (v/v) water; 50% (v/v)
hCPR;
5 mM trisodium-citrate****

10
vol%

8 wt%

100

hCPR was prepared under an Institutional Review Board-approved protocol at the
University of Memphis (approval IRB #/date: H11-16/September 9, 2010) through
methodology adapted from White and Jennings [14]. All steps were performed at room
temperature unless otherwise stated. Whole blood (120 ml) was obtained by venipuncture
from each of five informed, consenting graduate student participants into 30 cc syringes
and gently mixed with citrate buffer in 50 ml conical polypropylene tubes. Plasma and
buffy coat supernatants were collected after a ten minute low-speed centrifugation (600
g). Platelets were then concentrated in plasma by a fifteen minute higher speed
centrifugation (2,000 g), removal of top acellular plasma (80% volume reduction), and
resuspension into the residual plasma. Platelet-rich plasma (PRP) was pooled, and
clotting was induced through the addition of 10% (wt/v) calcium chloride (50 µl/ml of
PRP). Clot formation was allowed to proceed for one hour at 37° C. hCPR was expelled
from the clot, sterile syringe filtered (0.20 µm), and stored at -80° C until time of use.
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The in vitro test specimens of the current study were made by placing 1.5 ml of
sodium alginate (Sigma P/N 71238; St. Louis, MO) solution at twice the final weight
percentage in a 3 cc syringe. A separate syringe containing 125-150 µm TCP granules
(Plasma Biotal; Derbyshire, UK), the major setting reagent calcium sulfate dihydrate (as
USG® Terra Alba (United States Gypsum Company; Chicago, IL)), and 1.5 ml of hCPR
(with or without USP grade sodium citrate (Mallinckrodt Baker Inc.; Phillipsburg, NJ))
was then coupled to the alginate containing syringe, followed by mixing (~15 passes).
Upon homogenizing, the material was positioned into one of the syringes and allowed to
cure for a minimum of ten minutes. After curing, the ejection port of the syringe was
removed, and composite expelled (Figure 1a).
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Figure 1. Cylindrical Specimens Of F1+ Obtained From Syringe Mixing
a. F1+ formulation is shown ten minutes post-mixing. The biomaterial has cured and is
being expelled from a 3 cc syringe body with the ejection port removed. 0.5 ml sections
were cut from these ejected cylinders and used as test specimens. b. 0.5 ml F1+ culture
specimen is shown in 60 mm tissue culture plastic Petri dish containing TIB-71
RAW264.7 mouse monocyte cell line. Care was taken to minimize movement of the
material specimens as monocytes are easily dislodged from the surface. Although more
difficult to transport without specimen shifting, laying the cylinders along their lengths
enabled more material surface/media contact and avoided material contact with dish lids.

All in vitro specimens were prepared using sterile materials. Alginate solutions
were autoclaved for twenty minutes under slow venting in 40 ml aliquots using 50 ml
conical polypropylene tubes. Calcium salts were preloaded into syringes and exposed to
low-dose gamma irradiation. Sodium citrate (for F2+ and F2-) was sterile filtered as a
solution; required amounts were for each mix were filled into sterile 3 cc syringes with
~1.5ml of head room and fitted with a sterile syringe filter, frozen (-80° C), and
lyophilized in an upright position.
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4.2 Monocytes and Nitric Oxide In Vitro Assays: Microscopy, Griess Reagent, and
qRT-PCR
In vitro temporal induction of an inflammatory response due to material exposure
was assessed using the TIB-71TM RAW264.7 cell line (ATCC; Manassas, VA). The
transformed line was derived from an Abelson leukemia virus-induced tumor in the
BALB/c strain and exhibits a monocyte/macrophage phenotype with receptor activator of
nuclear factor kappa-beta ligand (RANKL)-induced osteoclast-like differentiation
potential [15]. All cultures were maintained in 10% (v/v) fetal bovine serum- (FBS-)
supplemented high glucose Dulbecco’s Modified Eagle’s Medium (DMEM-HG)
containing 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml amphotericin B.
Cells were expanded in T-flasks and passaged by scraping cells off the flask with a
rubber policeman and replating at 4x104 cells/cm2. Experimental cultures of 106 cells
were seeded onto 60 mm tissue culture plastic Petri dishes in 5 ml of medium and
allowed to attach overnight. On the following day, Petri dishes were randomly assigned
to one of five groups (n = 9/group): 1) untreated, time zero basal condition; 2-4) exposure
to 0.5 ml cylinders/dish of F1+, F2+, or F2- (Figure 1b); and 5) 5 µg/ml
lipopolysaccharide (LPS) (Simga P/N L4516) nitric oxide (NO) proinflammatory
endotoxin control.
NO production was assessed through media nitrite levels. Basal measurements
were taken as time zero (n = 9; group 1) and after 5, 24, and 48 hours of treatment
exposure (n = 3/group/time point; groups 2-5). Media nitrite levels were resolved using
the Griess Reagent System (Promega Corp.; Madison, WI) per the manufacture’s
protocol. Individual sample values were taken as the average of duplicate measures.
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Upstream changes in inducible (type II)-nitric oxide synthase (iNOS) gene
expression were determined on duplicates. mRNA was isolated from cells and subjected
to qRT-PCR to investigate changes in the iNOS gene expression. Immediately after
performing the Griess assay, media and materials were discarded from dishes, and
monolayers were gently rinsed with phosphate-buffered saline (PBS) and scrapped into
the rinse. For time zero measures, cells for each qRT-PRC sample condition (n = 2) were
obtained from the populations of four dishes by combining in a 15 ml conical tube, and
for all other time points, samples (n = 2 per condition) were obtained by splitting cells
from one of the three replicates between the two conical tubes. Cell pellets were formed
by centrifugation, and the supernatant was aspirated. Cells were then rinsed again through
resuspending in PBS. Cells were then centrifuged, and the supernatant aspirated
completely. Pellets were stored frozen (-80° C) until time of analysis.
Upon collecting and freezing all groups, pellets were thawed and RNA was
isolated using the RNeasy Mini Kit (Qiagen; Germantown, MD) with on-column DNA
digestion using RNase-free DNase Set (Qiagen). RNA (4.9 µg) was reverse transcribed
into cDNA using the RT2 First Strand Kit (Qiagen) on a Mastercycler® ep gradient
(Eppendorf; Hamburg, DE) thermocycler. qPCR (25 µl) was then performed on an
iCycler iQTM (Bio-Rad; Hercules, CA) to determine threshold cycle (CT) values using 1.5
µl of each cDNA sample using 1.5 µl of each (sense and anti-sense) 10 mM primer
solution (Integrated DNA Technologies; Coralville, IA) (Table 2), 12.5 µl SYBR®
Green/Fluorescein qPCR Mastermix (Qiagen), and nuclease-free water. cDNA
corresponding to one gene was amplified per well, and cDNA for iNOS and
housekeeping genes ribosomal 18s (Rn18s) and beta-actin mRNAs were amplified for all
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samples. Additionally, efficiency curves were created for each primer pair using the serial
dilutions of a common cDNA sample.

Table 2. Primer Pairs Used for qRT-PCR
Primer pairs were designed using Integrated DNA Technologies' on-line PrimerQuest
software and NIH's GenBank®. Data associated with Beta-Actin measures were
discarded due to poor efficiency.
efficiency
gene
direction
nucleotide sequences
(E)
sense
antisense

5'- TAG GTC GAT GCA CAA CTG GGT GAA -3'

iNOS

sense
antisense

5'- TAT TGC TCA ATC TCG GGT GC TGA -3'

Rn18s

BetaActin

sense
antisense

1.71

5'- TCT TTG ACG CTC GGA ACT GTA GCA -3'

1.65

5'- CCA GAG CGA AAG CAT TTG CCA AGA -3'
5'- ACT CCT GCT TGC TGA TCC ACA TCT -3'

2.64

5'- TCG TAC CAC AGG CAT TGT GAT GGA -3'

Photomicrographs were acquired at 40x, 100x, and 200x for all groups and time
points using an EVOS® xl Microscope (AMG; Bothell, WA) to assess morphological
changes.
4.3 Numeric Data Analysis
Changes in NO concentrations and iNOS expression as an effect of treatment
group and time in culture were assessed using SAS® Software (SAS Institute; Cary, NC).
NO concentrations were subjected to full factorial two-way ANOVA (α = 0.05) to detect
factor significance using the proc glm procedure. Factor levels were further investigated
for differences (α = 0.05) using Tukey HSD (main factors) and Tukey-Kramer
(interaction factor) multiple comparison testing of the means and the least-squared
means, respectively. qRT-PCR data were transformed prior to ANOVA. Efficiency curve
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data were used to determined the adjusted cycle threshold (CT) values [16], and ∆CT
values were calculated taking Rn18s as a housekeeing gene. ∆CT values were then
linearized to proportions (relative to Rn18s) per standard ∆CT methodology. Dummy
variables ranging -1 to 1 were assigned to treatment groups such that differences in the
average (Rn18s relative) proportion values were linearly reflected in the differences of
the assigned values spanning the two unit range. Linearized proportion values were then
used for modeling of the system; data were modeled as a second-order response surface,
proc rsreg procedure, where time was taken as a quadratic and linear independent
variable, treatment as an independent linear covariate, and the linearized proportions as
the response (or dependent variable). Canonical analysis of the model was used to
characterize the surface (stationary point and eigenvalues), and ANOVA (α = 0.05) for
the developed model was used to detect significant effects of the factors.
4.4 Ex Vivo Delivery
Deliverability, cohesion, and localization of the F1+ injectable composite were
assessed in Ca-2 and -3 rat caudal vertebrae. F1+ was chosen as a worst case due having
a higher weight percent of solids. Rat tails were harvested post mortem from animals
enlisted in an unrelated Institutional Animal Care and Use Committee-approved study
and stored in ethanol until time of use. A 4 cm opening was created along the tail in the
anterior-posterior direction using a scalpel, penetrating skin and the underlying ligament.
The soft tissue was spread to create access the vertebral bodies. Small openings were
created in the cortical shells approximately 1.5 mm distal the vertebral endplates using a
tooth burr and drill. A small amount of the F1+ material was delivered via injection
through a 16-gauge needle. Using a µCT 40 (Scanco USA, Inc.; Wayne, PA) and
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associated software 3D reconstitution, analysis of the vertebrae and implant locations
were performed. An area containing only the implant was partitioned and the volume
percent TCP and TCP granule degree of anisotropy (DA) was reported on using the
software functions.
5. RESULTS
5.1 Monocyte Culture and Microscopy
Cultures from all groups were composed of cells which typically exhibited a
spherical morphology with the occasional occurance of cell spreading/flattening onto the
tissue culture plastic. F1+ and F2- groups demonstrated a relatively consistent
morphology at all time points as only a small portion of the cells demonstrated spreading,
and those spreading cells typically had a spindle-like shape. These round and spindle
morphologies and population percentages were similar to the overnight-attached cells at
time zero. After 48 hours the majority of cells still exhibited a spherical morphology, but
cells in the F2+ and LPS groups, appeared larger. Occasional cells in F2+ and LPS
cultures were irregular, flattened, and spread with more filopodia compared to the F1+
and F2- cultures and basal condition (Figures 2a and 2b).
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Figure 2. Various Cell Morphologies Exhibited By The TIB-71 RAW264.7 Mouse
Monocyte Cell Line
Original magnification 200X. Bar = 127 µm. a. F1+ exposure at the 48 hour time point
showing minor amounts of cell spreading and the small round morphology associated
with the unactivated monocytes from time zero cells which had been allowed to attach
overnight. These morphologies were typical of F1+ and F2- treatments at all time points
and that of time zero. b. F2+ exposure at the 48 hour time point showing increased
monocyte activation through increased size in the spherical morphology, an increased
proportion of spread/flattened cells, and a more irregular spreading pattern with extensive
filopodia. These morphologies were typical of F2+ and LPS treatments at the late 48 hour
time point when nitrite accumulation had peaked.

5.2 Monocyte NO Production
Measurements associated with NO production were normalized against the
average basal level of nitrite at time zero (3.5 ± 0.9 µM) and are shown in Figure 3. The
effects of treatment, time in culture, and interaction term were all found to significantly
increase NO concentrations (p < 0.0001 for all factors). Exposure to F2+, F2-, and LPS
all induced a significant accumulation of NO by at least 48 hours of exposure (p <
0.0001, 0.02, and 0.0001, respectively). Averages associated with F2+ and LPS
treatments reached ten times that of the time zero basal level. Cultures exposed to LPS
showed significant accumulation after only 24 hours of treatment (p = 0.0036). Although
cultures exposed to F1+ demonstrated an average accumulated nitrite level twice that of
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time zero at 48 hours, significant differences between F1+ levels and the basal condition
were not detected in any of the multiple comparisons analysis. Although F2- was
significantly increased over that of the basal condition, no difference in accumulation was
detected between it and the F1+ condition at any time point. The analysis suggested that
the presence of hCPR bioagent in combination with lower weight percent alginate and/or
higher volume percentages of TCP (F1+) maintained a basal NO production rate in
monocytes in comparison to that seen associated with 5 µg/ml LPS endotoxin exposure
(and F2+). Whereas, accumulation in the F2+ group (hCPR, higher weight percent
alginate, and lower volume percentage of TCP) reached levels comparable to that of LPS
after 48 hours.

Figure 3. NO Production As Nitrite Accumulation In TIB-71 RAW264.7 Mouse
Monocyte Cell Line
Data are shown relative to the basal time zero level of 3.5 ± 0.9 µM nitrite and indicated
in the figure at the 100% value. Columns show average percentages and bars indicate ±
one standard deviation. Data were investigated through a full factorial two-way ANOVA
and Tukey tests (α = 0.05, for all). The LPS endotoxin treatment induced a statistically
significant increase between exposure times and represents a strong inflammatory
response associated with a bacterial infection. Significant differences between the F2+
and LPS exposure were not found at any time point, indicating a strong inflammatory
response from F2+ exposure. No significant differences were detected between F1+
exposed cultures and that of the basal levels overall or at any given time point, indicating
no detectable response in association with this hCPR-containing biomaterial. In the
absence of hCPR, the F2- exposed groups produced an intermediate response.
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5.3 Monocyte iNOS Gene Expression Patterns
The expression of the iNOS gene in response to the various treatments and culture
times was modeled using tranformed qRT-PCR data. Data reduction was performed using
the ∆∆CT method (CT indicates primer efficiency (Table 2) adjusted threshold cycle
values were used) and Rn18s as the housekeeping gene. Given the large efficiency value
associated with the beta-actin primer pair, data associated with its gene expression were
taken as erroneous and disregarded. Fold change values in mRNA expression as
compared to the time zero, basal expression level are shown in Figure 4. An upregulation
of iNOS was seen for all treatment groups by least 24 hours, the time point which
corresponded with each treatment’s maximum measured expression level. LPS, and
possibly F2-, treatment(s) induced an early response showing increased transcription after
only five hours. iNOS expression levels fell in all groups between the 24 and 48 hour
time points. F1+, F2+, and F2- material groups had returned to or dropped below the
basal expression level at the late 48 hour time point.
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Figure 4. qRT-PCR Fold Change iNOS Expression In TIB-71 RAW264.7 Mouse
Monocyte Cell Line
Result of material or LPS endotoxin exposure over time is shown. Data reduction was
performed using ∆∆CT analysis (standard ∆∆CT with the additional consideration primer
pair efficiency). ANOVA (α = 0.05) was applied to a second-order response surface
model in regards to time with treatment as a linear covariate on linearized ∆CT values. A
significant effect was found for each of the factors tested with that of material, and to a
lesser degree the quadratic term for time, being most influential on the model. F2+, F2-,
and LPS clearly demonstrated upregulation of the iNOS gene due to treatment. All group
averages peaked at the 24 hour exposure time point which is in agreement with the 21.7
hour exposure maximum found on the response surface model, but in consideration of
F2+ NO data, its peak may have occurred after the 24 hours, resulting NO accumulation
similar to LPS at 48 hours (Discussion section and Figure 3).

Response surface modeling of the linearized ∆CT values indicated significant
effects of all factors and accounted for 81% of the variance (R2-value). The covariate
material model parameter demonstrated a significance model effect (p < 0.0001). Time
was found to significantly affect the data through a second-order model in which both the
linear and more so the quadratic parameters were significant (p = 0.0078 and 0.0017,
respectively). The quadratic parameter for time and that of the covariate were most
influential in the model as their values were estimated to be -0.375 and 0.448 (all
variables coded for comparison), respectively, as compared to the much smaller linear
time parameter estimation of -0.072 (variables coded for comparison). Additionally,
canonical analysis of the model demonstrated negative eigenvalues, corresponding to a
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maximum linearized ∆CT response of 0.62 on the surface at the coded stationary point
value of -0.096, corresponding to 21.7 hours of exposure. This analysis was generally in
agreement with the nitrite findings of this study and demonstrated that the presence of
hCPR bioagent in combination with lower weight percent alginate and/or higher weight
percentages of TCP reduced the inflammatory response when compared to that induced
by the endotoxin. As before the F2- material, without hCPR, resulted in an intermediate
response. Although, iNOS mRNA transcription in response to F2+ activation did not
reach the level seen with the endotoxin, unlike nitrite accumulation level measures which
were similar to LPS group.
5.4 Ex Vivo Delivery
Injection delivery of F1+ into rat Ca-2 and -3 vertebrae through a burred hole was
successfully accomplished, and the TCP component was clearly distinguishable from the
native bone due to the increased radiopacity (Figures 5a and 5b). Figure 5c shows a 3D
rendering of the delivered material in situ; automated software analysis of this bolus
calculated a TCP volume percentage of 22.8%, only 2.8% higher than theoretical
formulation calculations (Table 1). The low DA value of 1.04 was also calculated with
the software and was in agreement of the spherical nature of the TCP granules (DA = 1
being a perfect sphere). Images and calculations showed that the material was able to
localize as a bolus within cancellous bone through a minimally invasive injection
delivery procedure.
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Figure 5. µCT Radiographic And Rendered Images Of Injection Delivered And In Situ
Cured F1+ Material
Delivery within the cancellous region of a rat Ca-2 vertebrae is shown. TCP granules can
be seen as the material with higher radiopacity and indicated implant localization.
Morselized trabeculae can be seen adjacent to the implant (arrows), indicating
cohesiveness of the curing material as it is being delivered. a. Radiographic image
showing anterior-posterior section. b. Radiographic image showing transverse section. c.
Rendered image of implanted material. 22.8% (v/v) was calculated for TCP granules
compared to the formulation theoretical value of 20% (v/v), indicated homogenization of
the mixed material is preserved during injection.

6.0 DISCUSSION
Biomaterial-induced remodeling of diseased, poorly vascularized bone to that of
healthy is hypothesized as an early prevention to spine, knee, and hip joint degeneration.
This treatment would require a proinflammatory response early after implantation, and
two proposed hCPR-containing alginate/TCP biomaterials have been assessed for such,
in vitro . Immune cell-mediated resorption of bone, and bone graft substitutes when used,
are requirements for osseous tissue remodeling; this necessity is apparent based on
natural and material-aided stages of fracture repair [9, 10, 17]. Monocytes are of
particular interest because of their ability to terminally differentiate into osteoclasts, a
special type of macrophage capable of bone and implant resorption upon biochemical
proinflammatory activation [18-20]. The inclusion of hCPR within the biomaterials was
anticipated to induce a proinflammatory response in vitro as the releasate-associated
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bioagents (hormones, growth factors, cytokines, and chemokines) diffused from the
osteoconductive composite matrix into the surrounding culture media [21-23]. Varying
degrees of activation and temporal aspects were expected due to the formulations
exhibiting different diffusion rates. Different diffusion rates result from the diverse
alginate weight percentages and, possibly, protein physicochemical interactions with
varied total TCP granule surface areas of the two formulations.
In addition to hCPR-mediated responses, it was recognized that alginates induce
an inflammatory response. The degree of response is related mainly to the purity, but
also, mannuronic to guluronic (M:G) monomer ratio, and molecular weight of the
polysaccharide copolymer [24, 25]. Nunamaker et al. reported on the wound response
and associated fibrous tissue capsule formation around alginate discs implanted three
months subcutaneously in rats [24]. The capsule thickness was reported to range between
15-35 µm[24] and deemed a mild response. They sourced their raw sodium alginate from
NovaMatrix (Norway), providers of an ultrapure grade of alginate. In contrast, our study
used Sigma-Aldrich BioReagent grade, a mid-range purity product from a medical grade
perspective. Given the source of our alginate, we anticipated an additive effect on
monocyte activation between the alginate and hCPR. This response was seen in our
evaluation of the higher 8% (wt/v) polymer weight percent F2+ and F2- formulas. This
higher weight percentage was selected for inclusion without hCPR as a proinflammatory
material control from a component percentage stand point (higher alginate weight
percentage versus F1+). F1+ was hypothesized to be associated with an accelerated hCPR
effect due to the higher diffusion coefficient of the 2% (wt/v) alginate compared to that of
F2+ which contained four times the weight percentage in the hydrogel phase.
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Additionally, LPS was included to produce a strong inflammatory response associated
with bacterial infections.
In vitro findings were only partially consistent with our presumptions. Patterns in
the upstream iNOS expression were predictive of downstream NO accumulation in the
subsequent time points within material groups; LPS, F2+, and F2- groups demonstrated a
classic increase in iNOS gene expression followed by an increase in NO production [19].
Although cumulatively, magnitude patterns in iNOS and NO accumulation were
inconsistent. NO measures for F2+ at 48 hours were not predictable based on the mild 24
hour upregulation of gene expression, suggesting continued upregulation of iNOS after
24 hours for F2+ cultures, unlike F1+, F2-, and LPS groups which indicated an earlier
peak, agreeing with the decoded surface response model stationary point (21.7 hours).
The NO levels of F2+ were comparable with those of the LPS proinflammatory
endotoxin control after 48 hours of exposure, demonstrating the largest downstream
inflammatory response among the material groups. F1+ and LPS NO production
remained below and above that of F2-, respectively, corresponding with their gene
expression patterns. In fact, F1+ cultures suggested an absence of inflammation as both
mRNA and NO accumulation remained nearly equivalent to that of the basal, time zero
values. iNOS expression suggested hCPR to partially suppress inflammation as F1+ and
early F2+ iNOS mRNA levels were generally below that of F2-. Although, the increased
alginate percentage of F2+ and F2- did correspond with an increase over basal iNOS
expression by 24 hours, and NO accumulation was noted as early as 5 hours for the
higher alginate percentage groups. These observations suggest NO production may have
been regulated at multiple levels, as is known to occur in vivo [21]. F1+ data indicate
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biologic factor regulation early in the signaling cascade between receptor activation and
gene transcription, as iNOS gene was not upregulated to any appreciable degree from the
material or hCPR, an unexplained observation in light of the F2+ and F2- data. Variations
in alginate and/or TCP percentages allowed for tunability of inflammation through near
complete suppression (F1+) and maximum activation (F2+).
This unforeseen suppression of monocyte activation by hCPR-containing F1+
elicits a closer look into the role of platelets with regard to inflammation. In a recent
work, Semple et al. gave a thorough, up-to-date review of known platelet-immune system
interactions [21]. Recent discoveries of plasma membrane-associated proteins such tolllike receptors (TLRs) and triggering receptor expressed on myeloid cells 1 (TREM) have
unveiled their major roles in the activation of neutrophils and monocytes [21, 26-29].
Aside from containing plasma membrane particulate, hCPR contains a multitude of
soluble growth factors, cytokines, and chemokines derived from the exocytosis of platelet
granules. Most of these soluble factors are not associated with monocyte activation but
are more directed toward chemotaxis, immunosuppression (such as transforming growth
factor-beta (TGF-β)), wound healing, and growth inhibition [21]. Mitani et al. showed the
ability of TGF-β to reduce NO production in RAW264.7 clones without reducing iNOS
expression [30], which may parallel the lack of accumulation with time seen for F1+
cultures. Potentially, an increased release rate of TGF-β or other hCPR-derived
immunosuppression factor from F1+ may have suppressed the activation mechanism(s)
associated with the F2+ increased response as limited diffusion of TGF-β (or others) from
the denser F2+ formulation allowed for NO production to occur. Different elution
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profiles and the preservation of bioactivity of these agents from the experimental F1+ and
F2+ materials may explain the opposing and wide spanning results of this study.
Additionally, Gruber et al. reported the in vitro induction of osteoclastogenesis in
bone marrow cells upon exposure to platelet releasate through upregulation of RANKL
[31]. RANKL signaling is required for osteoclastogenesis, and levels required to induce
differentiation in RAW246.7 clones must be added exogenously in vitro [15, 32].
Although monocyte activation by releasate-containing materials is possible, as
demonstrated by F2+ in our study, differentiation to an osteoclast-like phenotype was not
considered, due to an absence of RANKL in our model.
Our formulations have been designed for implantation within cancellous bone, a
tissue rich in both yellow and red marrow which contain stem and other mesenchymal
and hematopoietic cell types [33, 34]. Given this range of cell populations that would be
exposed to these materials upon delivery, it is difficult to translate our immediate in vitro
findings to longer-term in vivo responses where RANKL and other signals are expected
to be present and influential of slower differentiation processes. However, it was apparent
that the TCP and/or alginate material can induce some inflammatory response, and that
inclusion of hCPR may help regulate the extent to which this occurs through suppression,
as with F1+, or promotion, as with F2+.
The formal analysis methodology of the iNOS expression pattern may be foreign
to some readers, and as such, the authors would like to demonstrate appropriateness to
these readers and reflect on possible signaling phenomenon. Figures 6 and 7 show the
linearized ∆CT data in 2D plots. Figure 6 shows how coding the categorical treatment
variable allowed for linearization in this dimension; linearized ∆CT values increase
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(iNOS upregulation) from -1 (F1+) to 1 (LPS). Figure 7 demonstrates the parabolic
dependency of time on the linearized ∆CT data as values obviously peak at the 24 hour
time point. Although, time is also coded in the response surface procedure so that
parameter estimates may be compared among different variables directly with taking
variable value ranges into consideration, as done in Monocyte iNOS expression patterns
portion of the Results section. This rise and fall nature of the gene expression may be
related to either an endocytosis process in which inflammatory agents are being depleted,
receptor internalization and downregulation, or receptor desensitization from
overactivation of the signal transduction pathway. These graphs clearly show the
dependent linearization of the data against the independent covariate material and the
parabolic response of the data in regards to exposure time. These observations validate
the selection of a second-order response surface model with incorporation of a covariate.

Figure 6. Linearized ∆CT Measures For iNOS With Rn18s Taken As A Housekeeping
Gene Plotted Against Coded Treatment Values
Coded values (F1+ = -1; F2+ = -0.98; Basal (time zero) = -0.94; F2- = -0.57; LPS = 1)
are shown along x-axis. Coded values span -1 to 1 and are propotionally spaced based on
the mean response differences. A linear dependence of material is evident after
performing this linear transformation of the categorical treatment data and was included
as such in the formal analysis. Upregulation of iNOS transcription is evident for the F2and LPS treatment groups.
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Figure 7. Linearized ∆CT Measures For iNOS With Rn18s Taken As A Housekeeping
Gene Plotted Against Exposure Time
Given the average relative increase in iNOS by the 24 hour time point followed by
downregulation back to levels comparable to that of basal (time zero), a parabolic
function was chosen to describe this response in the formal analysis. The data are
somewhat skewed to the left of the 24 hour time point which was also reflected in the
response surface model which demonstrated a maximum value at 21.7 hours of exposure
time.

The ex vivo delivery portion of the current work served to assess deliverability of
the biomaterials to an implant site. µCT images and software analysis demonstrated that
these materials can be mixed and localized in the cancellous bone regions within the
vertebrae of small rodents. Wang et al. have demonstrated similar delivery capabilities
within rat tail vertebrae using injectable calcium sulfate cements and µCT [35]. Analysis
of TCP volume percentages show the homogenous mixture is maintained during the
injection delivery process; the alginate portion of the material is not extruded through the
osseous matrix while leaving the TCP granules behind. Also the increased radiopacity of
the TCP over the native bone allows for obvious radiographic identification of material,
easing complications commonly associated with localization using minimally invasive
systems and post-operative tracking of the material.
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7. CONCLUSION
Biomaterial-induced remodeling of unhealthy subchondral and cancellous bone,
which underlie degenerating joints, may serve as an early prevention to the onset of joint
failure, and the initial, and required, inflammatory response associated with implant and
tissue resorption has been considered. Variations in the alginate and/or TCP granule
component percentages of our injectable formulations resulted in altered release profiles
of hCPR-associated bioactive agents, allowing for the regulation of monocyte cell line
activation in vitro, modeling an inflammatory response with aspects paralleling those of a
fracture hematoma.
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ABSTRACT
Underlying changes in subchondral and cancellous bone precede joint
degeneration in spinal discs, knees, hips, and other joints. We hypothesize that an early
bone remodeling intervention therapy may alleviate or postpone the later manifestation of
joint failure. Utilization of a novel biomaterial for injection deliverability to the
underlying subchondral and cancellous bone during the onset of osseous changes, prior to
severe cartilaginous damage, is proposed. In this preliminary study we introduced novel
platelet releasate-containing alginate / calcium phosphate composites for this intervention
therapy and evaluated them in vitro through mesenchymal stem cell biocompatibility and
induction of osteochondral differentiation. DNA quantification and gene expression
profiles suggested mesenchymal stem cells were directed along an osteochondral
differentiation pathway, more specifically, to the immature nonhypertrophic chondrocyte
phenotype. These conclusions were based on reduced mitogenic activity, a rapid
upregulation followed by suppression of Runx2 transcription factor mRNA, sustained
upregulation of Sox9 transcription factor, and the absence of late marker expressions for
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both mature articular chondrocytes and osteoblasts over the course of fourteen days.
Initial findings in regard to the use of these materials for bone remodeling were positive
and support the execution of future studies evaluating the inflammatory and angiogenic
aspects of the materials. In this study, we have considered one of the many aspects of the
endochondral ossification process; neovascularization and resorption of bone with an
irregular physiology need to be evaluated.
INTRODUCTION
Catastrophic failure of the hyaline cartilage associated with spinal disc endplates
and the articular surfaces of knees and hips as result of degenerative joint disease is
foreshadowed by changes in the underlying subchondral and cancellous bone.
Subchondral plates thicken as the tidemark (bone/cartilage interface) advances,
decreasing the diffusion rate of cell nutrients into and waste products out of the hyaline
surfaces1-3. Trabecular bone mineral density also increases, taking on an altered
architecture and becoming brittle2. This bone often becomes necrotic in the knees and
hips4,5. As the disease conditions progress and microcracks in the subchondral plate
worsen, non-native vasculature invasion is induced within the joint, leading to the
presence of nerve tissue, osteophytes, cysts, and erosions (Schmorl nodes in the spine),
manifesting clinically in association with debilitating pain1,2,6.
We hypothesize early intervention to these osseous changes would preclude the
advancement of joint degeneration. We propose a novel, injectable, bioactive,
bioresorbable material with the design of delivering autologous bioactive agents within
the underlying subchondral and cancellous bone of these high risk joints in conjunction
with the onset of degenerate osseous changes. Preliminary treatment of unhealthy bone
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could potentially eradicate the later, painful stages of joint degeneration experienced by
patients.
The material is an in situ curing alginate hydrogel / osteoconductive calcium
phosphate granule composite scaffold which has been partially hydrated with human
concentrated platelet releasate (hCPR). The composite scaffold was produced with the
intention of minimally invasive delivery of the hydrogel scaffold composite into
thickened and necrotic cancellous bone, adjacent to the subchondral plate. Release of
hCPR factors locally from the materials will induce remodeling of the existing affected
bone and vasculature using the native vessels and stem cell populations, both
mesenchymal and hematopoietic in nature.
hCPR was selected for inclusion based on the natural self-healing capability and
processes of the body, ease of autologous acquisition, and cost effectiveness in
comparison to recombinant protein sources. The first step in fracture healing is the
inflammatory stage in which a hematoma is formed7-9. The hematoma contains activated
platelets which release cytokines, chemokines, and growth factors, initiating
inflammation and associated immune and reparative cell recruitment10. The proposed
materials act similar to a hematoma and the pro-healing processes associated with such
have inspired development of the hydrogel scaffold composite. hCPR is obtainable from
a patient’s whole blood using a centrifugation or apheresis separation technique followed
by platelet activation, processes familiar to the clinic11-13. Platelets are first separated
from whole blood and plasma, and then activated with calcium, forming a clot. The
releasate solution is expelled from the clot for inclusion in the biomaterial. It is
envisioned that after release of the incorporated bioactive agents from the degrading
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alginate hydrogel portion of the biomaterial, the osteoconductive granules will provide
sites to encourage regeneration of the afflicted bone to a healthy, vascularized state.
hCPR contains cell signaling agents which induce chemotaxis, mitogenic, angiogenic and
/ or differentiation in the various cell types associated with bone remodeling and
regeneration, namely, fibroblasts, mesenchymal stem cells (MSCs), osteoblasts,
macrophages, monocytes, and endothelial cells9,14.
The biomaterial-associated inflammatory process is expected to induces de novo
vascularization and infiltration of mesenchymal cells for repair and remodeling as is seen
with hematomas. The proposed angiogenic ability of the composite scaffold would allow
for invasion of monocytes which are actively involved in the remodeling process through
their capability of osteoclast and macrophage transformations15,16. This
neovascularization will also provide nutrients for the extracellular matrix-producing
mesenchymal cells9,15.
The current study is an initial in vitro evaluation of the biomaterial to determine
its effects on rat marrow-derived mesenchymal cells through measuring changes in cell
proliferation and gene expression. Specifically, advancement along an osteochondral
lineage with focus on the early differentiation of the endochondral ossification process
has been examined.
METHODS
Mesenchymal Stem Cells
Marrow aspirates from the femora of two young, skeletally mature (~350 g), male
Sprague Dawley rats were individually plated in three T-75 culture flasks per donor.
Femora were excised immediately postmortem from animals enrolled in an unrelated
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Institutional Animal Care and Use Committee (IACUC) approved study; NIH guidelines
for the care and use of laboratory animals were observed. On the following day flasks
were thoroughly rinsed with Hank’s balanced salt solution, and the subpopulation of cells
which had attached to the tissue culture plastic (TCP) were taken as MSCs17,18. In several
of the authors’ past experiences, use of TCP adherent cells has resulted in a
subpopulation which, at least a substantial portion of the cells, demonstrates a stem-like
phenotype19,20. Colonies were expanded to 80% confluence of first passage in 10% (v/v)
FBS-supplemented DMEM-HG containing 100 IU/ml penicillin, 100 µg/ml
streptomycin, and 2.5 µg/ml amphotericin under normal culture conditions (37˚C; 5%
(v/v) CO2; 100% RH). At second passage cells from each donor were combined and used
for experimentation.
Biomaterial
We developed two complimentary experimental formulations (Table 1) of an
injectable, in situ curing, alginate-based composite system containing 125-150 µm betatricalcium phosphate (CaPO4) granules (Plasma Biotal Ltd.; Derbyshire, UK).
Osteoconductive granules were incorporated within a continuous alginate (Fluka; St.
Louis, MO as sodium alginate) hydrogel matrix21. In the first experimental formulation
F1+ the hydrogel component was at a lower polymer weight percentage and was in lower
volumetric proportion to that of the particulate compared to F2+. In contrast, the
hydrogel portion of the second experimental formulation F2+ was at a higher polymer
weight percentage and was combined with granules occupying a lower volume
percentage compared to F1+. A small amount of Terra Alba calcium sulfate dihydrate
(USG; Chicago, IL) was included in each formulation to induce curing. F2+ had a minor

58

amount of sodium citrate included to improve workability of the material during delivery.
hCPR was incorporated such that it accounted for half of the hydrogel volume in both
experimental F1+ and F2+ composite formulations. The ranges chosen for the polymer
weight percentage of the hydrogels and volume percentages of the granules covered the
ranges which produced cohesive gels capable of ejection through a 16-gauge needle.

Table 1. Materials, Composition Proportions, And Study Role For Each Of
The Formulations Tested
*Volume percent of 125-150µm granules is based on theoretical β-tricalcium phosphate
density of 3.14 g/cm3.
**Weight percent is based on gel volume only (granules volume was not considered).
***L/P is equal to gel volume in milliliters divided by calcium sulfate dihydrate mass in
grams.
****Molarity is based on gel volume only (granules volume was not considered).
βCalcium
Tricalcium Sodium
Formulation
Role
Liquid
Sulfate
Phosphate Alginate**
(L/P***)
Granules*
50% (v/v) water;
Experimental
20% (v/v)
2 wt%
300
F1+
50% (v/v) hCPR
Evaluation

F2+

Experimental
Evaluation

50% (v/v) water;
50% (v/v) hCPR;
5 mM trisodiumcitrate****

F1-

Material
Control

100% (v/v) water

10% (v/v)

8 wt%

100

20% (v/v)

2 wt%

300

hCPR was prepared using a methodology similar to that described by White and
Jennings and under an Institution Review Board (IRB) approved protocol22. All human
subjects enrolled for the hCPR production protocol provided written informed consent
which under approval of our Institutional Committee on Human Research (approval:
H11-16; date: September 9, 2010). hCPR consisted of pools from four or five
participants’ preparations. All steps were conducted at room temperature.
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Approximately 120 ml of blood was collected from each participant by venipuncture into
acid citrate dextrose (ACD) and separated in 30 ml aliquots. Aliquots were centrifuged at
160 g for ten minutes. Plasma and buffy coat were collected and separated into 10 ml
aliquots. Platelets were separated from the plasma through centrifugation at 2,000 g for
fifteen minutes. Cell-free plasma was removed from each tube leaving 2 ml (platelet
pellet volume and plasma volume combined). Platelets were resuspended in remaining
plasma and pooled. Clotting was then induced by the addition of 50 µl 10% (w/v)
calcium chloride per each 1.2 ml of the platelet suspension. Clotting was performed for
one hour at 37˚C. The fibrin clot was then drained and removed from the hCRP. hCPR
was sterile filtered at 0.20 µm and stored at -80˚C in 1ml aliquots until time of use.
All biomaterial test specimens were made using sterilized materials and originated
from the same raw material lots, excluding hCPR which came from single blood
collection pools for each of the two experiments. The components were mixed in
syringes, and 1 ml of composite gel was delivered via a 16-gauge needle to 12-well
culture plates where gel discs were allowed to cure for fifteen minutes prior to adding
MSCs and growth medium to the wells.
14 Day Proliferation Study
Cell proliferation was assessed through lysate DNA quantity measures using the
Quant-iTTM PicoGreen® dsDNA kit (Invitrogen Corp; Carlsbad, CA) per the
manufacturer’s instructions. Specimen values were taken as the average of duplicate
measures.
5x104 MSCs were seeded onto F1+ and F2+ experimental material surfaces and
standard TCP for monolayer expansion in polystyrene culture plates (Corning; Corning,
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NY). Cultures were allowed to expand for zero, three, seven, and fourteen days on the
material surfaces and the manufacturer treated plastic surfaces. Cultures were maintained
under the same medium and environmental conditions described above, and 2.2 ml
medium per well was refreshed every three or four days.
Cell lysates from each condition (material and time point) were collected (n=3);
nine 5x104 MSC specimens were taken for time zero, allowing for a balanced
experimental design. Collection protocols varied due to release of cells from the
materials becoming more challenging with time in culture. Media was first aspirated
from the wells and specimens were rinsed with HBSS. MSCs were easily collected from
TCP control wells via mild trypsinization in the presence of ethylenediaminetetraacetic
acid (EDTA). Cells were collected from experimental materials through multiple
treatments with varying concentrations of trypsin, never exceeding 2.5% (w/v), in the
absence of EDTA, avoiding dissolution of the hydrogels. Collected cells were pelleted
and lysed in deionized water. Lysates were stored at -80°C until time of analysis.
14 Day Osteochondral Differentiation Study
MSC differentiation along osteochondral and fibroblastic lineages was studied
through gene expression changes. Quantitative reverse transcription polymerase chain
reaction (qRT-PCR) was used to determine the materials’ ability to temporally modulate
mRNA expression. This allowed for distinction of the various chondrocytic phenotypes
of endochondral ossification and articular cartilage formation.
5x105 MSCs were seeded onto F1+, F2+, or control material (F1-) in culture
plates and maintained under the same medium and environmental conditions described
above. F1- was identical to F1+ with the exception of sterile water replacing hCPR,
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accounting for 100% of the gel liquid component. Cell pellets from each material (n=2)
were collected as described above after five hours, one, three, seven, and fourteen days in
culture. MSC pellets (n=2) containing 5x105 cells were retained at time zero to serve as
the undifferentiated control gene expression. Pellets were stored at -80°C until time of
analysis.
SABiosciencesTM (Germantown, MD) and Qiagen (Germantown, MD) reagents
were used per manufactures’ instructions to perform qRT-PCR. RNA was isolated from
cell pellets using the RNeasy Mini Kit (Qiagen). Typically, recovered RNA was
subjected to a second pass over new spin columns to remove PCR-interfering
contaminants, which were likely alginate and/or calcium ions per conversations with the
manufacturer. On-column degradation of DNA was conducted during the first pass using
the RNase-free DNase Set (Qiagen). Reverse transcription was performed with the RT2
First Strand cDNA Kit (SABiosciences) on a Mastercycler® ep gradient (Eppendorf;
Hamburg, DE) thermal cycler. Real-time PCR was performed in custom built primer
plates (SABiosciences) with SYBR® Green Master Mix (SABiosciences) on an iCycler
iQTM Real Time PCR Detection System (Bio-Rad; Hercules, CA) to determine cycle
threshold (CT) values. Gene expressions of interest are listed in Table 2. Additionally,
each sample was subjected to genomic DNA contamination, reverse transcription, and
polymerase chain reaction control reactions on the custom built plates. CT values greater
than thirty-five were taken as “no call”.

62

Table 2. Genes Studied In qRT-PCR Differentiation Study
Genes have been grouped based on their role / interpretation in regards to the study. The
gene symbol and various other unofficial names are given.
Purpose

Osteogenic

Osteochondral

Gene
Symbol

Alias

Official Full Name

Runx2

Cbfa1

Runt-related transcription factor 2

Sp7

Osx

Sp7 transcription factor (osterix)

Sparc

-

Secreted protein, acidic, cysteinerich (osteonectin)

Bglap Bglap2/Bgp/Bgpr/Bgpra

Bone gamma-carboxyglutamate
(gla) protein (osteocalcin)

Alpl Akp2/MGC93545/PHOA

Alkaline phosphatase,
liver/bone/kidney

Col1a1

COLIA1

Collagen, type I, alpha 1

Acan

Agc/Agc1

Aggrecan

Sox9

-

SRY-box containing gene 9

Col2a1

CG2A1A/COLLII

Collagen, type II, alpha 1

Eng

MGC124909

Endoglin (CD105)

Chondrogenic
MSC marker
Fibrogenic

18A2/42A/CAPL/MTS1/
S100a4
P9ka/PEL98/RNP9KA

S100 calcium-binding protein A4
(fibroblast-specific protein 1
(FSP1))

Actb

Actx

Actin, beta

Gapdh

Gapd

Glyceraldehyde-3-phosphate
dehydrogenase

Housekeeping

Data Analysis
Proliferation data were analyzed with JMP® Statistical Discovery Software (SAS
Institute; Cary, NC). DNA values were subjected to a full factorial two-way analysis of
variance (α=0.05) to detect effects of culture substrate, time in culture, and their
interaction. Post-hoc analyses using Tukey’s HSD method (α=0.05) were performed to
identify differences between factor levels.

63

Fold change in gene expression was calculated using the delta delta Ct (∆∆Ct)
method, where β-actin served as the housekeeping (reference) gene for normalization and
time zero MSCs served as the control group. Delta Ct (∆Ct) values were subjected to
statistical analysis with SAS® Software (SAS Institute; Cary, NC) using linear mixedeffects models through the PROC MIXED procedure and Minimum Variance Quadratic
Unbiased Estimation (MIVQUE0 option). Weight percent alginate and presence of hCPR
were taken as fixed effects and time in culture was taken as a random effect. Interaction
terms were not considered. Significant fixed effects were detected using Type III Sums
of Squares F-tests (α=0.05) with Satterthwaite approximations for denominator degrees
of freedom and further subjected to Tukey’s HSD post-hoc tests (α=0.05) to detect
differences among the factor levels. Significance of the random variable was detected
using the Wald Z-tests (α=0.05) on the variance parameter estimates on the diagonal of
the covariance matrices (COVTEST option); p-values were taken as half of that reported
due to testing at the boundary condition (variance equal to zero).
RESULTS
14 Day Proliferation Study
The MSC growth study demonstrated material cytocompatibility through
maintained viability early after exposure to the material and biocompatibility through
proliferative behavior later in the study (Figure 1). Growth patterns associated with both
experimental formulations and positive control TCP demonstrated very similar patterns
with material presence hindering expansion rate. Significant effects of both the time in
culture and culture substrate main factors and their interaction (p<0.0001 for all) were
detected in the model (p<0.0001). Initially, average DNA values declined after seeding
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when compared to day three (p=0.0002), but after the day three time point all groups
significantly increased throughout the study. Sequential levels of time in culture
(differences between days three and seven; differences between day seven and fourteen)
revealed highly significant increases in DNA quantities (p<0.0001 for both). Post-hoc
testing of the interaction levels among culture substrates and times further clarified the
materials roles in altered proliferation rates. Cells on TCP were the only group to
demonstrate a significant interaction effect between days three and seven; differences
between time points within the two experimental material cultures where not detected
until the later day seven to fourteen comparisons (p<0.01 for both). MSCs cultured on the
experimental formulation materials demonstrated a partially suppressed proliferation rate,
as positive control TCP DNA values were significantly greater than experimental values
at each time point after three days in culture. No statistical difference was detected
between the experimental formulation groups at any given time point.
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Figure 1. Proliferation Data Consistent With Nonhypertrophic Chondrocytes
Group averages (n=3) and +/- one standard deviation are shown. 5x104 second passage
rat mesenchymal stem cells were seeded onto 1ml samples of the experimental materials
or onto tissue culture platic (TCP). Cultures were maintained for the various time points
shown. DNA was quantified in lysates using a commercial kit which employed
fluorescent dye binding. All groups exhibited an initial small loss in viability by day
three (p = 0.0002) but group averages continued to rise thereafter. The proliferation rates
on the concentrated platelet releasate-containing alginate / calcium phosphate composite
materials were similarly reduced (p = 0.1082) in comparison to the positive control
monolayer culture on the TCP (p < 0.0001). This continued proliferation is consistent
with gene expression results (shown in Figure 2) suggesting cells displayed a
proliferative nonhypertrophic chondrocyte-like phenotype.

14 Day Osteochondral Differentiation Study
Both the experimental materials containing hCPR (F1+ and F2+) and the control
material without hCPR (F1-) demonstrated the ability to alter the gene expressions of
second passage MSCs in comparison to time zero undifferentiated monolayer TCP
cultures (Figure 2).
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Figure 2. Fold Changes In mRNA Expression Suggestive Of Mesenchymal Stem Cell
Differentiation Along An Osteochondral Pathway, Specifically, Immature
Nonhypertrophic Chondrocytes
Average fold change (n=2) and +/- one standard deviation as compared to second passage
monolayer rat mesenchymal stem cells are shown. Results from the studied genes of
interest are shown in the various bar graphs; collagen II and osterix mRNA results are not
shown as their expression was absent. 5x105 second passage rat mesenchymal stem cells
were seeded onto 1ml samples of the experimental materials (F1+ and F2+) or onto a
control material (F1-) similar to F1+ (shown in Table 1) with water replacing the
concentrated platelet releasate portion. Cultures were maintained for the various time
points shown. A quick burst of Runx2 followed by upregulation of Sox9 is consistent
with early endochondral bone formation process where mesenchymal stem cells taking
on the nonhypertrophic chondrocyte phenotype. Maintaining the expression of Sox9 as is
seen in F2+ cultures in the absence of later hypertrophic chondrocyte, articular
chondrocyte, and osteoblast markers (indicated in Table 2) indicate that cells are
retaining this immature phenotype. Interestingly, mesenchymal stem cell markers were
upregulated throughout the study due to the materials themselves but to a lesser degree
from the suspected faster growth factor eluting F1+ group. Additionally, a fibroblast
phenotype was disregarded with the lack of change of the fibroblast-specific protein.
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Relative mRNA levels of the master transcriptions factors of osteochondrogenesis
Sox9, Runx2, and osterix were followed throughout the study. Sox9 expression
increased in each material group over the first three days of culture. F2+ specimens
demonstrated a dramatic 175 average fold increase on day three and heavily contributed
to observed significant effect of alginate weight percent in the formal analysis (p = 0.022
factor level; p = 0.026 post-hoc difference between 8 and 0 weight percent). Remaining
above reference MSC levels of Sox9 mRNA, F2+ and F1- values declined after the day
three peak; whereas the F1+ group demonstrated an absence of Sox9 expression on days
seven and fourteen. Runx2 expression for F1+ and F2+ cultures increased over MSCs
and peaked at day one and five hours, respectively; it was undetectable in cells cultured
on the F1- control material throughout the study and in experimental materials after
peaking. In contrast to Sox9 findings, F1+ material demonstrated a superior ability to
induce Runx2 mRNA expression at 8.3 average fold increase. Osterix expression was
only detected in one of the two MSC reference samples at the high CT (low quantity)
value of 32.7 and was “no call” for all other sample reactions (data not shown). Given
the limited number of observations in the Runx2 and osterix models, n = 7 and n = 1,
respectively, statistical analysis of these data was uneventful in the fact that no significant
effects were detected with limited samples.
Both phenotype-specific and more generalized osteochondral protein encoded
mRNAs were followed over the fourteen day study. Osteoblastogenesis was assessed
through osteonectin and osteocalcin gene expression. Osteocalcin expression was
upregulated in experimental material cultures with that of F2+ showing the greatest
average fold increase of 7.7; it was not detected after the five hour time point in these
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groups or at any time point for the F1- control group, resulting in a lack of observations
for meaningful statistical analysis. Osteonectin gene expression was found throughout
the experiment for all groups but was upregulated in the F2+ and more so in the F1groups but only at day one. Measurements were suggestive a loss with time (p = 0.058)
as seen after day one in all groups, and the presence of hCPR was found to inhibit
osteonectin gene expression (p = 0.0003). The more generalized osteochondral mRNAs
for alkaline phosphatase, collagen I, and aggrecan proteins were pursued. Collagen I was
upregulated on average between 1.5 and 2.0 fold over MSCs at five hours and day one;
after which, expression declined to below the 1x reference value, accounting for an
observed significant loss with time in culture (p = 0.043). Alkaline phosphatase
expression was highly variable at the five hour and day one time point for all (F1+, F2+,
and F1-) and experimental (F1+ and F2+) materials, respectively. Complete inhibition of
alkaline phosphatase expression was seen after 5 hours for F1- control material but
persisted out to the day one time point for experimental hCPR containing materials.
Aggrecan gene expression may have been upregulated in the F1- material group at five
hours in culture but was suppressed in all groups after day one. As previously discussed
for other genes, the lack of observations associated with alkaline phosphatase and
aggrecan mRNA models resulted in no significant effects being detected. Articular
chondrocyte-specific collagen II expression was absent from all experimental, control,
and reference MSC expression measures.
Additionally, the MSC-related surface integrin endoglin (CD105), fibrogenic
protein S100a4 (fibroblast-specific protein (FSP)), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA expressions were monitored. Interestingly, CD105
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mRNA was found to be significantly upregulated by the presence of hCPR (p < 0.0001),
and no effect was found in the FSP gene expression model. Noteworthy, GAPDH gene
expression in this model was found to be unstable and not acceptable as the housekeeping
gene.
DISCUSSION
The initial in vitro assessment of novel, injectable composite biomaterials
containing hCPR and CaPO4 within a continuous alginate matrix as an early intervention
to degenerative joint disease has been undertaken with MSCs. Half of the hydrogel
volume was composed of hCPR, serving as a source of bioactive agents. MSCs were
successfully cultured on the composite biomaterials for fourteen days demonstrating
biocompatibility. A gene expression study was conducted looking at the materials
potential to induce in vitro differentiation down an osteochondral lineage in a commonly
employed growth medium containing calf serum.
In an attempt to convey a more coherent discussion we have created Table 3 for
the readers’ reference and to avoid confusion in use of the general term “chondrocyte”
has been negated for terminology adapted from Provot, namely nonhypertrophic
chondrocytes, hypertrophic chondrocytes, and articular chondrocytes23.
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Table 3. Summary Of Major In Vitro Findings And Associated Relevancies Abbreviated In Regard To Formulations
Formulation(s)
Formulations
Exhibiting
Cellular Interpretation
Event(s)
Tested
Event
-Cell expansion at termination
of experiment

F1+, F2+

F1+, F2+

-Experimental materials are biocompatible and cytocompatible

-Similar expansion patterns to
TCP monolayer at a reduced
rate

F1+, F2+

F1+, F2+

-Mitosis-related metabolic activity reduced in the presence of
dynamic differentiation-related gene expression changes

F1+, F2+

-Non-biologic and biologic formulation components have induced
reorganization of intracellular activity as a priority
over mitosis

-Lack of expansion between
day 3 and 7 time points

F1+, F2+

-Upregulation of Sox9
expression through at least day F1+, F2+, F13
-175-fold average increase in
Sox9 at day 3
-Unsustained burst of Runx2
upregulation by at least day 1

-8.3-fold average increase in
Runx2 at day 1

F1+, F2+, F1-

F1+, F2+, F1-

F1+, F2+, F1-

F1+, F2+, F1- -Onset of osteochondral differentiation

F2+

-Strong push into the immature nonhypertrophic chondrocyte
phenotype

F1+, F2+

-Initial push along osteochondral pathway with a transcription factor
typically associated with osteoblast terminal
differentiation

F1+

-Superior ability to maintain upregulation of gene associated with
terminal osteoblast differentiation of nonhypertrophic chondrocytes
versus rapid burst associated with induction of
Sox9 expression
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Table 3. Summary Of Major In Vitro Findings And Associated Relevancies Abbreviated In Regard To Formulations (cont.)
Formulations Formulation(s)
Event(s)
Cellular Interpretation
Tested
Exhibiting Event
-Experimental and control materials, alone, cannot induce
-Nonexistent expression of
F1+, F2+, F1- F1+, F2+, F1- terminal osteoblast differentiation of MSCs in vitro
Osterix
-Potentially involved in reduced proliferative behavior of MSCs
on the experimental materials
-Lack of continuous osteo-nectic
and collagen type-I upregulation
-Non-biologic materials and, more so, hCPR bioactive agents
-Lack of upregulation and, more F1+, F2+, F1- F1+, F2+, F1inhibited terminal osteoblastogenesis and held differentiating
so, disappearance of oseocalcin
MSCs in the immature nonhypertrophic chondrocyte phenotype
and alkaline phosphatase
expression by day 3
-Disappearance of aggrecan
expression
F1+, F2+, F1-

F1+, F2+, F1-

-Experimental and control materials, alone, cannot induce
terminal hypertrophic chrodrocyte differentiation of MSCs in
vitro

-Absence of collagen type-II
expression
-Upregulation of MSCassociated surface integrin
CD105

F1+, F2+, F1-

F1+, F2+, F1-

-Cells either remained somewhat "plastic" in terms of their
phenotypes
OR
-Cell population was inhomgeneous with some differentiating and
others retaining the MSC phenotype
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It was anticipated that MSCs would demonstrate an immature nonhypertrophic
chondrocyte phenotype early after exposure to the material while moving away from that
of a MSC, due to eluted hCPR growth factors. Unclear, though, was how and if these
cells would mature in vitro as the growth factors associated with the hCPR were expected
to be depleted through regular media changes and what effects, if any, would the alginate
and calcium phosphate materials have on MSC differentiation in the absence of hCPR.
Platelet releasate preparations are known to contain multiple cell signaling proteins14,24,25,
but given the MSC differentiation nature of the current study, growth factors are the most
pertinent. Specifically, the presence of platelet derived growth factor isoforms (PDGFs),
basic fibroblast growth factor (FGF), and transforming growth factor-beta isoforms
(TGF-βs) are thought to be of greatest relevance26 among this pool of ligands as they are
highly involved in MSC mitogenic, chemotactic, and phenotype commitment.
To study differentiation and the extent of such we followed the expression of
three key transcription factors associated with chondrogenesis, namely Sox9 and Runx2,
and osteogenesis, namely Runx2 and osterix. An early elevation of Runx2 expression,
followed by continuing Sox9-mediated inhibition is consistent with the onset of MSC
osteochondral differentitation. First MSCs become immature chondroblasts and then
take on the uncommitted nonhypertrophic chondrocyte phenotype. Runx2
phosphorylation in MSCs is required to initiate the phenotypic shift of these cells along
the osteochondral pathway27,28. It is upregulated again later through the BMP pathways
(Smad, ERK, and JNK) in mature hypertrophic chondrocytes, leading to osteoblast
differentiation and continuous Runx2 expression which becomes associated with osterix
gene expression27,28. Neither the rebound of Runx2 nor expression of osterix was seen in
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the current study. Nonhypertrophic chondrocyte phenotype is induced and maintained
through Wnt, TGF-β, and FGF signaling pathways which lead to the upregulation of
Sox9, responsible for commitment, proliferation, and suppression of hypertrophic
chondrocyte conversion28-30. Suppression of advancement to the hypertrophic phenotype
is maintained by Sox9 which was shown by Cheng and Genever to induce lysosome
compartmentalization and degradation of Runx231. Additionally, repression of Runx2
expression through Sox9-mediated upregulation of a homolog of Drosophila bagpipe
(Bapx1) has been shown in MSC chondrogenesis micromass cultures32,33. This Sox9
expressing nonhypertrophic chondrocyte phenotype is more consistent with our findings.
Both experimental materials containing hCPR exhibited expression patterns
consistent with reaching the early nonhypertrophic chondrocyte stage of differentiation.
Interestingly, Sox9 upregulation was seen in the negative control F1- material cultures
(no hCPR). Although unlike when hCPR was present, Runx2 was completely shut off at
all time points for F1-. F2+ material appeared to induce a faster and more robust
differentiation through an increased and prolonged Sox9 expression over all groups after
a quick rise followed by complete inhibition of Runx2. This inhibition began at some
point between the five hour and one day time points. It is anticipated that growth factors
would be eluted from the F1+ and F2+ materials under different release profiles. These
differences are expected due to the enhanced diffusion barrier presented by the four fold
difference in the solid weight percentages of the gel formulations and less so through
physiochemical interactions between the proteins and two fold varying volume
percentages of CaPO4 granules between them. It is speculated that a slower and
extended release rate would be found from F2+ material and may account for the
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continuous and increased Sox9 expression, as excessive signaling (as may be associated
with F1+) is known to desensitize and internalize many types of receptors34.
A lack of maturation to osteoblasts or articular chondrocytes is apparent based on
the absence of either a late osterix/Runx2 combinatorial expression or collagen II
expression, respectively, and the observed continued proliferative behavior of Sox9
expressing cells throughout the study. This behavior is consistent with in vitro and in
vivo studies with nonhypertrophic chondrocytes. Interestingly, early time points
suggested minor upregulation of osteogenic markers, namely osteocalcin, osteonectin,
alkaline phosphatase, and collagen I. Osteocalcin and alkaline phosphatase expression
was quickly shut off, and alkaline phosphatase and collagen I expression fell from early
time points. This response may be the result of the early, but short, Runx2 expression
seen in hCPR containing materials or a response to the osteoconductive nature of calcium
phosphate biomaterials35,36 as some of these upregulations were seen in the F1- control
material also. There was no evidence of maturation along an articular chondrocyte or
fibroblast phenotype as collagen II and FSP expression were absent and unaffected,
respectively, in all specimens. Unanticipated, the MSC marker CD105 was shown to be
upregulated early in the hCPR-containing cultures as a result of the materials themselves
but to lesser degree in the suspected faster growth factor eluting F1+ group.
We speculate that implantation of these experimental materials within a boney
site such as the subchondral and cancellous bone region adjacent to a joint (spine, knee,
or hip) would lead to terminal osteogenic differentiation of MSCs. Advancement to later
stages of endochondral ossification or articular chondrocytes within our in vitro model
was not seen and is known to require growth factors such as bone morphogenic proteins
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(BMPs) or TGF-βs. Of these, only TGF-βs are expected to be present at a meaningful
quantity in our culture model, and removal of the majority of active TGF-βs through
routine media changes is highly probable at the later time points when their presence at
active levels above that which is expected to be in 10% (v/v) FBS-supplemented medium
(1 to 2 ng/ml total latent and active TGF-βs) would be required37,38. Typically, in vitro
differentiation studies use a minimum of 5 ng/ml of a active TGF-β (isoform one or
three) in a serum-free medium to induce a chondrocyte-like phenotype from MSCs39.
Although from an in vivo perspective, the presence of native growth factors and
hormones such as BMPs, estrogen, vitamin D, and parathyroid hormone is anticipated to
be present and should induce osteoblast terminal differentiation in the marrow MSC
population local to the implant as would be seen in normal fracture healing7,27.
A lower, yet still positive, expansion rate was seen for the cells cultured on the
experimental F1+ and F2+ and control F1- materials in comparison to TCP monolayers.
The rapid expansion of immature osteochondral cells is well known to be associated with
the role of the zinc-finger transcription factor osterix, downstream from Runx and absent
from all test groups’ gene expressions40,41. Additionally, and poorly understood are the
expression and functional relations between the non-collagenous bone proteins bone
osteopontin (bone sialoprotein) and osteonectin. Osteopontin was not followed, but
osteonectic expression was noted throughout the study for F1+, F2+, and F1- with
upregulation for F2+ and F1-. Typically, the expression of these two bone-related
proteins are associated with one another42, and osteopontin is known to inhibit
proliferation43,44. These occurrences suggest that either the lack of osterix or the potential
presence of osteopontin, or both, may have accounted for the lower rate of cell expansion
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compared to the monolayer culture on TCP. Also, TCP is designed for cellular adhesion
and spreading45,46; whereas, alginate does not accommodate cell integrin interactions and
spreading47.
In conclusion, this preliminary study evaluated the biocompatibility and
osteochondral differentiation potential of our injectable hCPR-containing alginate /
CaPO4 composite using rat marrow-derived MSCs. We found MSC cultures to quickly
take on a phenotype consistent with nonhypertrophic chondrocytes based on gene
expression profiles and continued mitogenic activity. Future studies examining
inflammatory responses in monocytes and MSCs along with angiogenic capabilities using
endothelial cells will further our investigation of the capability of the potential of these
materials to regenerate subchondral and cancellous bone with intention of reversing joint
degeneration.
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Chapter 5. Conclusions
Two variations of an injectable, in situ curing biomaterial have been developed
for delivery within the unhealthy subchondral and cancellous bone regions adjacent to
osteoarthritic spinal disc, hip, and knee joints. These formulations were designed to
initiate and compliment the remodeling of osseous and vascular tissue through both the
autologous bioagent-induced cellular responses from native and circulatory cell
populations and the osteoconductive nature of the biomaterial itself, respectively. The
biomaterial is composed of a human concentrated platelet releasate (hCPR)-containing
alginate hydrogel which incorporates granules of β-tricalcium phosphate (β-TCP). The
alginate portion acts as an hCPR bioagent carrier and controlled release system, β-TCP
granule carrier, and curing agent for implant localization. This composite was designed to
function two-fold: mock a fracture hematoma in the hours to days period post-injury and
provide a β-TCP osteoconductive scaffold for subchondral and cancellous bone
remodeling in the weeks to months timeframe.
Fracture healing occurs in consecutive, overlapping stages of which hematoma
formation is the initiation step known as the inflammatory stage and lasts on the order of
one to two weeks as the hematoma is overturned32,34. The hematoma is a blood clot
within the fracture and serves as a source of cytokines and growth factors. Within a clot,
the majority of these bioagents is derived from activated platelets and initiate an immune
response35-37. Inclusion of hCPR within the biomaterial has demonstrated in vitro
activation of a monocyte cell line in the current work based on gene expression, protein
production, and chemotaxis studies. Monocytes are of particular interest for the current
work as they are an immature phenotype capable of differentiation into macrophages and
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further onto osteoclasts31,38-40. Macrophages and osteoclasts are expected to be the initial
cellular responders in both unhealthy bone and implant resorption for the proposed
resorbable biomaterial application. Growth factor release from the faster resorbing
alginate portion of the biomaterial has been demonstrated, successfully paralleling that of
a hematoma.
Associated with fracture-induced immune responses is that of angiogenesis,
where neovascularization occurs. Vessels within bone serve two purposes: supply and
removal of metabolic constituents and provide a route for yellow and red marrowproduced stem cells (mesenchymal and hematopoietic) to traverse throughout the body41.
Both of these functions are relevant for both fracture healing and the proposed bone
remodeling therapy of the current work. New vessels must form to provide immune cells
within the implant location as it degrades and accommodate the metabolic activity of
both the resorbing (osteoclasts) and rebuilding (osteoblasts) cells lines required for
remodeling of calcified bone tissue. In vitro assessment of angiogenic qualities of the
material has been demonstrated. Monocyte transendothelial migration has been induced
by material eluates, suggesting the ability to delivery immune cells. Endothelial cell
chemotaxis and haptotaxis activity have also been induced in the presence of the
biomaterial eluates. Collectively, these in vitro responses are consistent with the in vivo
induction of vessel budding and angiogenesis31,32,34,42.
Delivery of the implant within the subchondral/cancellous bone region has been
demonstrated via micocomputed tomography (µCT) in the rat vertebrae and suggests the
displacement of bone (at least within the cannula path) and the associated marrow to the
periphery of the implantation site. Established from this imaging-based assumption,
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osteoblasts and, more importantly, mesenchymal stem cells (MSCs) are expected to be
adjacent to the implant and would be exposed the implant material immediately upon
placement. In terms of calcified tissue rebuilding, MSCs are of great importance due to
their plasticity for osteochondral phenotype differentiation and ability to proliferative
rapidly, compared to other mature mesenchymal cell phenotypes43-45. In vitro
biocompatibility and differentiation potential of the biomaterial has been shown with
MSCs which proliferated and produced dynamic gene expressions consistent with the
onset of osteochondral differentiation during a fourteen day study. These cellular
behaviors are consistent with the initial stages of endochondral ossification, the method
by which bone both develops early in life and heals in response to a fracture46-48. Given
these premature cell behaviors which correspond with osteoblast differentiation and the
presence of the osteoconductive β-TCP granules, it is presumable that new bone will be
laid throughout the implant region.
The exploratory in vitro and ex vivo studies strongly suggest that the experimental
implant materials have the potential ability to induce remodeling of cancellous and
subchondral bone in vivo. This phenomenon combined with the already known preceding
osseous changes associated with the onset of osteoarthric joints advocate in vivo
investigations of the biomaterial as an early intervention to the onset and progression of
this debilitating disease.
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Chapter 6. Recommendations
The current work is a detailed description of bench-, in vitro, and ex vivo studies
which assess two formulation variations designed from a more general biomaterial
concept. Beyond the current scope, the long-term ambition of this work is the
implementation of at least one of these formulations as a medical device for use in the
clinical setting. Obviously, prior to creating a medical device from such a biomaterial is
the scientifically and ethically derived needs for conducting preclinical studies. In vivo
assessment of novel and bioactive materials within a minimum of one animal model is a
requirement, and the current formulations are no exceptions. Typically, biomaterials are
first evaluated in small animals through proof-of-principle type studies, and, if findings
are successful, a larger animal model is pursued in a more extensive study.
Staying within the constraints of spinal disc degeneration, male Hartley guinea
pigs are known to develop osteoarthric lesions in knees, hips, and elbows over the first
year of life49-51, but anatomical and histological studies have not been performed on the
spine of these animals. It is likely that the intervertebral discs of these animals degenerate
with these other joints. If found to occur, this guinea pig may offer an improved model to
study disc degeneration therapies over other small animal models which use injury to
produce a compromised joint. Male Hartley guinea pigs at 4, 8, or 12 months of age
should be assessed for the onset of degenerative discs through methods such as peripheral
quantitative computed tomography and histology to detect changes in osteochondral bone
(e.g. mineral density, trabecular architecture, and cortex thickness), vascular, and disc
height throughout the lumbar spines as a result of age. Data should be used to estimate
the age at which degeneration begins to serve as time of implantation and to determine
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optimal spinal level for implantation. At the determined onset of degeneration, the
formulations should be delivered within vertebrae. Peripheral quantitative computed
tomography and histology may be used to monitor changes in osteochondral bone,
vascular, and discs to assess the ability of the biomaterials to inhibit or reverse
osteoarthritic degenerative changes. Success in these small animal models would
constitute further in vivo studies in larger animals such as goats or pigs prior to human
assessment in clinical trials.
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